

1-21-05

AF/JSW

COMBINED TRANSMITTAL OF APPEAL BRIEF TO THE BOARD OF PATENT  
APPEALS AND INTERFERENCES & PETITION FOR EXTENSION OF TIME  
UNDER 37 C.F.R. 1.136(a) (Small Entity)

Docket No.  
PENN-0065

In Re Application Of: Wolfe and Fraser

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
08/393,066	February 23, 1995	Deborah Crouch	26259	1632	1030

Invention: METHOD OF DELIVERING GENES TO THE CENTRAL NERVOUS SYSTEM OF A MAMMAL



01/24/2005 SSITHIB1 00000051 08393066

02 FC:2251

COMMISSIONER FOR PATENTS:

60.00 op

This is a combined Transmittal of Appeal Brief to the Board of Patent Appeals and Interferences and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing an Appeal Brief.

Applicant(s) hereby request(s) an extension of time of (check desired time period):

One month       Two months       Three months       Four months       Five months

from: December 21, 2004      until: January 20, 2005  
*Date*      *Date*

The fee for the Appeal Brief and Extension of Time has been calculated as shown below:

Fee for Appeal Brief: \$250.00

Fee for Extension of Time: \$60.00

**TOTAL FEE FOR APPEAL BRIEF AND EXTENSION OF TIME:** \$310.00

The fee for the Appeal Brief and extension of time is to be paid as follows:

- A check in the amount of \_\_\_\_\_ for the Appeal Brief and extension of time is enclosed.
- Please charge Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619
- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.
- If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 50-1619
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

BEST AVAILABLE COPY

COMBINED TRANSMITTAL OF APPEAL BRIEF TO THE BOARD OF PATENT  
APPEALS AND INTERFERENCES & PETITION FOR EXTENSION OF TIME  
UNDER 37 C.F.R. 1.136(a) (Small Entity)

Docket No.  
PENN-0065

In Re Application Of: Wolfe and Fraser

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
08/393,066	February 23, 1995	Deborah Crouch	26259	1632	1030

Invention: METHOD OF DELIVERING GENES TO THE CENTRAL NERVOUS SYSTEM OF A MAMMAL

TO THE COMMISSIONER FOR PATENTS:

This combined Transmittal of Appeal Brief to the Board of Patent Appeals and Interferences and petition for extension of time under 37 CFR 1.136(a) is respectfully submitted by the undersigned:

*Jane Massey Licata*

*Signature*

Dated: January 20, 2005

Jane Massey Licata  
Reg. No. 32,257  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053  
Tel: 856-810-1515  
Fax: 856-810-1454

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office  
(Fax no. ) on

*(Date)*

*Signature*

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a) on


*(Date)*

*Signature of Person Mailing Correspondence*

*Typed or Printed Name of Person Mailing Correspondence*

\*This certificate may only be used if paying by deposit account.

CC:



CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. **EV540196335US**

Date of Deposit: January 20, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop "AF", Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

- 1) Combined Transmittal of Appeal Brief to the Board of Patent Appeals and Interferences & Petition for Extension of Time Under 37 C.F.R. §1.136(a) (Small Entity) (in duplicate);
- 2) Appeal Brief (in triplicate);
- 3) Return Postcard; and
- 4) Credit Card Payment Form in the amount of \$310.00.

*Jane Massey Licata*  
\_\_\_\_\_  
JANE MASSEY LICATA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **PENN-0065**

Inventors: **Wolfe and Fraser**

Serial No.: **08/393,066**

Filing Date: **February 23, 1995**

Examiner: **Deborah Crouch**

Customer No.: **26259**

Group Art Unit: **1632**

Confirmation No.: **1030**

Title: **Method of Delivering Genes to the Central Nervous System of A Mammal**

"Express Mail" Label No. **EV540196335US**

Date of Deposit January 20, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop AF, P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**APPEAL BRIEF**

01/24/2005 SSITHIB1 00000051 08393066

01 FC:2402

250.00 OP

## TABLE OF CONTENTS

I.	Real Party in Interest . . . . .	1
II.	Related Appeals and Interferences . . . . .	1
III.	Status of Claims . . . . .	1
	The Prosecution History of the '066 Application . . . . .	2
	Placing The Status of the Claims in Context . . . . .	4
IV.	Status of Amendments . . . . .	7
V.	Summary of Invention . . . . .	7
VI.	Issues . . . . .	9
VII.	Grouping of Claims . . . . .	9
VIII.	Arguments	
	Issue: Whether the Specification Provides Sufficient Guidance on How to Deliver Genes to the Central Nervous System of Mammals	
1.	The Enablement Requirement Under 35 U.S.C. §112, First Paragraph, Has Been Met . . . . .	10
2.	Therapeutic <i>Utility</i> , Not <i>Benefit</i> , is the Appropriate Standard for Patentability . . . . .	11
3.	Working Examples of Every Embodiment of the Claimed Invention are Not Required Under Patent Law . . . . .	13
IX.	Conclusion . . . . .	14

Appendix 1 - Amended Claims

Appendix 2 - Declaration of Laura M. Plunkett, Ph.D.

Appendix 3 - Xing et al. (1994)

Appendix 4 - *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 1996, entire chapter of text in the *General Principles*

**I. Real Party in Interest**

The real party in interest is The Trustees of the University of Pennsylvania.

**II. Related Appeals and Interferences**

There are no related appeals or interferences.

**III. Status of Claims**

U.S. Application Serial No. 08/393,066, filed on February 23, 1995, is the subject of this appeal. This application is a continuation-in-part of Serial No. 08/020,177, which in turn was a file wrapper continuation of Serial No. 07/676,894.

This case was filed as a continuation-in-part in an earnest effort to facilitate the prosecution and allowance of this case. Appellants slightly revised the application to: (1) clarify the distinctions between the invention and the primary prior art reference, Dobson et al. (1989); (2) assist the Examiner in better understanding and characterizing the invention with respect to areas where there was obvious misunderstanding; and (3) assist the Examiner in evaluating the knowledge in the art at the time the invention was made and placing the invention in the appropriate context. A particular issue addressed was the difference between the central nervous system (CNS) and the peripheral nervous system (PNS). The Examiner's confusion about the difference between the CNS and the PNS was causing a significant misunderstanding of the invention. No additional subject matter was added to the case which is now on appeal. Accordingly, this case has been treated during the course of its prosecution essentially as a file wrapper continuation case by both parties.

### The Prosecution History of the '066 Application

In a first Office Action dated April 1, 1996, the specification and claims 1 through 9 were objected to under 35 U.S.C. §112, first paragraph, as failing to provide an enabling disclosure for delivering a gene to the central nervous system such that the host would receive a benefit from such delivery. Claims 1, 2, 5, and 6 were rejected under 35 U.S.C. §102(b) as being anticipated by Dobson et al. (1989). Claims 3, 4, 7, 8, and 9 were rejected under 35 U.S.C. §103 as being unpatentable over Dobson et al. (1989) in view of Nishimura et al. (1986).

A response to the first Office Action was filed on July 31, 1996. In this response, claim 1 was amended.

In a Final Office Action dated September 13, 1996, objection to the specification and rejection of claims 1 through 9 under 35 U.S.C. §112 were maintained. The Examiner again suggested that it was not apparent from disclosure that the method would sufficiently deliver a gene to the central nervous system such that the host would receive a benefit from such delivery. Claims 1, 2, 5, and 6 remained rejected under 35 U.S.C. §102(b) as being anticipated by Dobson et al. (1989). Rejection of claims 3, 4, 7, 8 and 9 under 35 U.S.C. §103 was also maintained over Dobson et al. (1989) in view of Nishimura et al. (1986).

A reply to the Final Rejection was filed on December 16, 1996 wherein claim 1 was amended.

In an Advisory Action mailed January 13, 1997, the pending §112, §102(b), and §103 rejections were maintained.

An Appeal Brief was filed May 12, 1997 to address the final rejection of claims 1 through 9 under 35 U.S.C. §112, §102(b), and §103.

In the Examiner's Answer mailed July 23, 1997, the rejection of claims 1 through 9 under 35 U.S.C. §112 was maintained and the rejection of claims 1 through 9 under §102(b) and §103 were replaced by a new ground of rejection under 35 U.S.C. §103(a) as being unpatentable over Dobson et al. (1989) in view of Nishimura et al. (1986).

A Reply Brief was filed on September 22, 1997. In this Brief, claims 1 and 8 were amended.

In a communication from the Examiner dated December 5, 1997, the Examiner rejected the claim amendments as they were not filed in an amendment after final under CFR §1.116.

An amendment after final was filed on December 17, 1997. In this amendment, claims 1 and 8 were amended.

A Remand to the Examiner from the Board of Appeals and Interferences was mailed January 17, 2003. Prosecution of amended claim 1 through 9 was recommended.

In a first Office Action dated October 11, 2002, claims 1 through 9 were rejected under 35 U.S.C. §112, first paragraph, as failing to provide an enabling disclosure for use of the claimed method of delivery absent a treatment or therapeutic effect. Claim 1 was rejected under 35 U.S.C. §102(b) as being anticipated by Palella et al. (1989). Claims 1 through 9 were rejected under 35 U.S.C. §103 as being unpatentable over Palella et al. (1989) and Dobson et al. (1989) in view of Nishimura et al. (1986).

A response to the first Office Action was filed on March 10, 2003. In this response, claim 1 was amended.

In a Final Office Action dated May 2, 2003, rejection of claims 1 through 9 under 35 U.S.C. §112 was maintained. Claims 1, 2, 4, 5, and 6 were rejected under 35 U.S.C. §102(e) as being anticipated by U.S. Patent No. 5,849,572. Claims 1 through 7 were

rejected under 35 U.S.C. §103 as being unpatentable over U.S. Patent No. 5,849,572 in view of Dobson et al. (1989). Claims 1, 3, 8 and 9 were rejected under 35 U.S.C. §103 as being unpatentable over U.S. Patent No. 5,849,572 in view of Dobson et al. (1989) and Guise et al. (1985).

A response to the final Office Action was filed on August 4, 2003. In this response, claims 1 and 8 were amended.

A request for a Continued Prosecution Application was filed on October 31, 2003.

In a first Office Action dated January 28, 2004, claims 1 through 9 were rejected under 35 U.S.C. §112, first paragraph, as failing to provide an enabling disclosure for gene therapy.

A response to the first Office Action was filed on April 28, 2004. In this response, claim 1 was amended and claim 2 was canceled.

In a final Office Action dated July 22, 2004, the rejection of claim 1 and claims 3 through 9 under 35 U.S.C. §112, first paragraph, was maintained.

The final rejection of claim 1 and claims 3 through 9 under 35 U.S.C. §112, first paragraph, is on Appeal. A copy of the claims involved in the Appeal is attached hereto as Appendix 1

#### **Placing The Status of the Claims in Context**

The parent application, Serial No. 07/676,894 was filed on March 28, 1991 with nine claims. Claims 1 through 9 were rejected in the first Office Action dated February 26, 1992. The specification was objected to and claims 1 through 9 rejected under 35 U.S.C. §112, first paragraph, as failing to provide an enabling disclosure. Specifically, the Examiner suggested that an undue amount of experimentation would be required of the skilled artisan

to implement the invention with a predictable degree of success. These comments related to the method for producing the plasmid. With respect to the claims (1 through 9), the Examiner suggested the disclosure was enabling only for claims limited to delivering a heterologous DNA sequence to mouse neuronal cells comprising administering to mice HSV-1, where said DNA sequence is regulated by the HSV-1 LAT promoter. The Examiner further suggested that undue experimentation would be required to extend the invention to other mammals. Claims 4, 5, and 7 were also rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter. The Examiner pointed to three phrases in the claims: "person", "modulating" and "genetically engineered". The Examiner rejected claims 1-3, 6 and 7 under 35 U.S.C. §102(b) as being anticipated by Ho et al. (1989). Finally, claims 4, 5, 8, and 9 were rejected under 35 U.S.C. §103 as being unpatentable over Ho et al. (1989).

A response to this first Office Action was filed on June 29, 1992 wherein amendments were made to the brief description of the drawings, the specification, and claims 4, 5, and 7.

In a Final Office Action dated September 22, 1992, the objection to the specification and rejection of claims 1 through 9 under 35 U.S.C. §112 were maintained. The rejection of claims 1-3, 6 and 7 under 35 U.S.C. §102(b) and claims 4, 5, 8, and 9 under 35 U.S.C. §103 were also maintained. Further, the amendments filed June 29, 1992 were objected to under 35 U.S.C. §132 because they introduced new matter into the specification.

On February 22, 1993 a continuation request was filed with the Patent Office under 37 C.F.R. §1.62 (FWC Request). The application, with claims 1 through 9, was accorded Serial No. 08/020,177 with a filing date of February 22, 1993.

A preliminary amendment was filed April 21, 1993 where the drawings, the specification, and the claims were amended. Claims 1 through 9 remained pending. The Appellants also addressed the Examiner's rejections under 35 U.S.C. §102(b), §103 and §112 in view of the amendments.

In the first Office Action dated October 27, 1993, the specification and claims 1 through 9 were rejected under 35 U.S.C. §112 because they failed to provide an enabling disclosure. Specifically, the Examiner suggested that the information provided in the specification failed to adequately enable a method of delivering genes to the central nervous system of animals and humans in general, and failed to enable the delivery and expression of therapeutic genes to alleviate a disease or condition. The Examiner also suggested a need to satisfy the requirements of enablement under 35 U.S.C. §112 by making a deposit of HSV-1 strain 17 under the terms of the Budapest Treaty because the strain was not publicly available. Claims 1 through 9 were further rejected under 35 U.S.C. §101 because the Examiner suggested they lacked patentable utility due to the unpredictable nature of the subject matter, *i.e.*, delivery of genes to the central nervous system. Claims 1-3 and 6-8 were rejected under 35 U.S.C. §102(b) as being anticipated by Dobson et al. (1989). The Examiner also rejected claims 3, 4, 5, and 9 under 35 U.S.C. §103 as being unpatentable over Dobson et al. (1989).

A response to the first Office Action was filed on February 28, 1994. Claims 1 through 9 were canceled and new claims 10 through 17 were added to more precisely define the invention and incorporate subject matter that had been canceled.

In a Final Office Action dated August 26, 1994, claims 1 through 9 were canceled and new claims 10 through 17 remained

pending. The specification and claims 10 through 17 were rejected under 35 U.S.C. §112 as failing to provide an enabling disclosure. The Examiner suggested that Appellants enabled only a method of delivering a DNA sequence to the brain of a mouse where the method comprises administration by corneal scarification of HSV-1 strain 17 containing a beta-glucuronidase cDNA sequence operatively linked to the LAT promoter. Appellants arguments were deemed persuasive to overcome the deposit requirement. The rejection of claims 10 through 17 under 35 U.S.C. §101 were maintained. Claims 10 through 17 also remained rejected under 35 U.S.C. §103 as being unpatentable over Dobson et al. (1989).

As this overview of the prosecution makes clear, the major area of concern is the sufficiency of the disclosure concerning how the gene is delivered to the central nervous system (CNS) and whether a therapeutic benefit is achieved upon delivery.

#### **IV. Status of Amendments**

The amendment filed on April 28, 2004 was entered upon filing of this appeal. A copy of the claims as amended in the response is attached hereto as Appendix 1.

#### **V. Summary of Invention**

The claimed invention is a method of delivering a gene of selected DNA sequence to the central nervous system (CNS) of a mammal by administering to that mammal a neurotropic virus, where the virus contains a selected DNA sequence under the control of a promoter which permits expression of the gene during the latent infectious state of the virus. The ability to introduce a gene into the mammalian CNS *in vivo*, and altering the physiology of the CNS, is an important advance in the field of neurobiology, as well as in

gene therapy for genetic diseases leading to neurological disorders. Neurotropic viruses, such as HSV-1, are useful vector systems because of features such as: 1) the ability to deliver a gene directly into post-mitotic cells; 2) a wide host range; and 3) maintenance indefinitely in a latent state in post-mitotic neuronal cells. The method of delivering genes to the central nervous system of a mammal would be suitable for application to a variety of neurological disorders (i.e., Lesch-Nyhan syndrome, mucopolysaccharidosis, other lysosomal storage diseases). Moreover, the method would be useful for delivery of a heterologous gene or selected DNA sequence that encodes a substance that alters any neurological function in a useful way, an example being the introduction of the tyrosine hydroxylase gene into Parkinson's disease patients to increase levels of dihydroxyphenylalanine (DOPA). Other examples of ways to use the method would include coding RNA designed to block expression of a gene and delivery of genes that encode compounds that bind receptors on neurons and alter cell function (e.g., blocking opiate receptors to modulate drug effects). Details in the specification demonstrate for the first time that a foreign gene can be delivered and expressed from a LAT promoter over a long period of time (i.e., greater than 4 months) in neurons of the CNS following peripheral infection with a neurotropic virus. This long-term expression of a foreign gene is an important advance that is particularly relevant to use of the claimed invention as a potential therapeutic. It has also been demonstrated that it is possible to correct a deficiency in biological function in cells of the CNS.

The method of the invention is described in detail at pages 9 through 20 of the specification. Information on the types and features of neurotropic viruses which support their use as vectors

are discussed at pages 10-13 and page 15 (lines 1-31). Features of the promoters capable of expressing the heterologous gene during the latent infectious state from the selected neurotropic virus are described in detail on pages 13-14. Specific emphasis on the LAT promoter of HSV-1 is presented. Description of the heterologous gene or selected DNA sequence suitable for delivery by the method of this invention is presented on page 15 (lines 33-37) and page 16 (lines 1-17); methods for cloning this sequence would be by any of a variety of methods known to those of skill in the art (see also Examples 1 and 2, pages 20-24). Delivery of cloned genes into targeted CNS neurons is described in detail on page 17 (lines 35-36) and pages 18-20. Examples 3-5 on pages 24-26 present *in vivo* evidence that a gene can be successfully delivered into targeted neurons of the CNS. More importantly, the expression of the delivered gene is not transient; the effect of the treatment was still evident more than 4 months after initial delivery of the gene in this mammal.

## **VI. Issues**

The issue on appeal is whether the specification and claim 1 and claims 3 through 9 are patentable under 35 U.S.C. §112, first paragraph.

## **VII. Grouping of Claims**

Claim 1 and claims 3 through 9 stand or fall together on the issue of whether the disclosure provides sufficient guidance under 35 U.S.C. §112, first paragraph concerning how to deliver a gene to the central nervous system of a mammal.

## VIII. Arguments

**Issue: Whether the Specification Provides Sufficient Guidance on How to Deliver Genes to the Central Nervous System of Mammals**

### **1. The Enablement Requirement Under 35 U.S.C. §112, First Paragraph, Has Been Met**

The enablement requirement refers to the requirement of 35 U.S.C. §112, first paragraph, that the specification describe how to make and how to use the invention. In accordance with MPEP §2164, the disclosure, when filed, must contain sufficient information regarding the subject matter of the claims as to enable one skilled in the art to make and use the claimed invention. In the present invention, the claims are drawn to delivery of selected DNA sequences to the central nervous system of a mammal comprising administering to peripheral neuron cells of a mammal a neurotropic viral vector which infects the central nervous system of a mammal so that the selected DNA sequences are stably expressed for at least four months by the infected central nervous system cells. The selected DNA sequence of the vector is operatively linked to a LAT promoter to facilitate stable expression. The present invention does not claim methods for treating a disease of the CNS, rather the subject matter of the instant claims relates to methods for stably expressing a selected DNA sequence in the central nervous system. In accordance with these claims, the specification sufficiently discloses each element of the claims including how to administer to peripheral neuron cells of a mammal (see, e.g., page 18, lines 3 to page 19, line 20 and paragraph bridging pages 19 and 20) a neurotropic viral vector which infects cells of the central nervous system of the mammal (see, e.g., paragraph bridging page 10 and 11 and page 15, lines 3-31), said vector containing a selected

DNA sequence (see, e.g., paragraph bridging page 9 and 10 and first paragraph of page 16) operatively linked to a LAT promoter (see, e.g., page 13, line 8 to page 9, line 35) so that said selected DNA sequence is stably expressed for at least four months by infected central nervous system cells. Further, the specification teaches the skilled artisan at least one use for the method of the invention (i.e., to correct a deficiency in a biological function in cells of the central nervous system). Accordingly, the instant specification must be viewed as containing sufficient information regarding the subject matter of the claims as to enable one skilled in the art to make and use the claimed invention.

**2. Therapeutic Utility, Not Benefit, is the Appropriate Standard for Patentability**

The rejection of claim 1 and claims 3 through 9 under 35 U.S.C. §112, first paragraph, has been maintained. The Examiner suggests that while the claimed invention requires only stable expression of the selected DNA sequence, the specification provides no use for mere stable expression. Although the Examiner admits that biologically active beta-glucuronidase is expressed when the DNA sequence for the enzyme operatively linked to the LAT promoter is contained in an HSV vector and is administered by corneal abrasion, the Examiner appears to doubt that such expression of the beta-glucuronidase would have an effect on the host mammal or be an effective treatment for a beta-glucuronidase deficiency. According to the Examiner, delivery is read in light of the specification as gene therapy and there is no disclosure for delivery absent a therapy. Therefore, the Examiner has rejected the specification and claim 1 and claims 3 through 9 on the basis of failing to show a therapeutic benefit in a host. The Appellants respectfully disagree

with the Examiner's analysis and conclusions.

Appellants respectfully point out that demonstration of therapeutic benefit is **not** a requirement of patentability. The case law is quite clear; Applicant does not have to prove that a correlation exists between a particular activity and an asserted therapeutic use of a compound as a matter of statistical certainty, nor does he or she have to provide actual evidence of success in treating humans where such a utility is asserted. MPEP 2164.02 states that "The mere fact that something has not previously been done clearly is not, in itself, a sufficient basis for rejecting all applications purporting to disclose how to do it." 822 F.2d at 1078, 3 USPQ2d at 1304 (quoting *In re Chilowsky*, 229 F.2d 457, 461, 108 USPQ 321, 325 (CCPA 1956)). Thus, the Examiner's requirement that the specification demonstrate a therapeutic effect or a benefit to the host is improper.

Instead, as the courts have repeatedly held, all that is required is a reasonable correlation between the activity and the asserted use. *Nelson v. Bowler*, 626 F.2d 853, 206 USPQ 881, 884 (CCPA 1980) and MPEP §2107.02. If one skilled in the art would accept the data provided as being reasonably predictive of utility in humans, evidence from these tests should be considered sufficient to support the credibility of the asserted utility. *In re Hartop*, 311 F.2d 249, 135 USPQ 419 (CCPA 1962); *In re Krimmel*, 292 F.2d 948, 953, 130 USPQ 215, 219 (CCPA 1961); *Ex parte Krepelka*, 231 USPQ 746 (Bd. Pat. App. & Inter. 1986). Further, in an earnest effort to advance the prosecution, Appellants even presented a Declaration by Dr. Laura Plunkett, one of skill in the art, which clearly stated that data provided in the instant specification are demonstrative of a pharmacological effect (delivery of a gene to the CNS of an animal and expression of that

gene) and thus, therapeutic utility (see specifically paragraphs 3 and 4 of Dr. Plunkett's declaration attached hereto as Appendix 2). Thus, contrary to the Examiner's suggestion, data provided in the instant specification provide one of skill in the art with assurance that the invention delivers genes to the central nervous system in accordance with the claims. The teachings of the specification can be used in conjunction with general knowledge in the art establishing strategies for use of this delivery system in humans as well as for the production of animal models as evidenced by Xing et al. (1994) (attached hereto as Appendix 3, for convenience). Further, confirmation of this approach can even be found in standard textbooks of medical pharmacology (e.g., *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 1996), where an entire chapter of text in the *General Principles* section is devoted to gene therapy; copy attached hereto as Appendix 4, for convenience). Clearly, pharmacologists view gene therapy as another tool for drug delivery that has reached the level of acceptance as one of many tools in pharmacology. Accordingly, the instant specification must be viewed as enabling one of skill in the art to make and use the invention to deliver genes to the central nervous system as claimed. It is not appropriate to dismiss the data and teachings of the specification because one is simply skeptical of the idea of gene therapy when there is objective evidence of successful application of the claimed method.

**3. Working Examples of Every Embodiment of the Claimed Invention are Not Required Under Patent Law**

The Examiner also suggests that other neurotropic viruses have not been shown to have a therapeutic effect in a host. As discussed above, however, any requirement for a demonstration of therapeutic

effect is legally improper. Working examples of every embodiment of the claimed invention are clearly not required. See MPEP §2164.02. The determination of the propriety of such a rejection involves a two-stage inquiry. The first stage is to determine how broad the claim is with respect to the disclosure. The second inquiry is to determine if one skilled in the art is enabled to make and use the entire scope of the claimed invention without undue experimentation. The specification clearly teaches at pages 10 and 11 and page 15 other neurotropic viruses which can be used in the present invention. Moreover, the art supports the predictability of using a vector of the present invention to stably express a selected DNA sequence for at least four months. For example, U.S. Patent No. 5,849,572 teaches that an HSV vector, similar to that taught in the instant application, provides transgene expression for up to 6 months post-inoculation. Thus, Appellants have shown that one of skill in the art is enabled to make and use the entire scope of the claimed invention without undue experimentation. The Examiner, however, has provided no reasonable basis for her suggestions. The requirements of 35 U.S.C. §112, first paragraph have been met as a matter of scientific and legal fact. Therefore, Appellants respectfully request reconsideration and withdrawal of this rejection.

#### **IX. Conclusion**

The Examiner has failed to establish that the requirements of 35 U.S.C. §112 have been met. Combining what is known in the art concerning delivery of genes through viral vectors such as HSV-1 and what is taught in the specification (see Examples 4 and 5, as well as pages 10-20 of the specification), one of skill in the art could use the claimed invention. It is not appropriate to dismiss

the data and teachings of the specification because one is simply skeptical of the idea of gene therapy when there is objective evidence of successful application of the claimed method. Appellants respectfully point out that the claims are limited to successful infection of a gene *in vivo* and expression of that gene, which has been clearly demonstrated in this case. Accordingly, it is requested that the objection to the specification and the rejection of claims under 35 U.S.C. §112 be withdrawn and this case be allowed.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: January 20, 2005

Licata & Tyrrell P.C.  
66 East Main St.  
Marlton, NJ 08053

(856) 810-1515

## APPENDIX 1

Claim 1 (previously presented): A method of stably expressing a selected DNA sequence in the central nervous system of a mammal comprising administering to peripheral neuron cells of a mammal a neurotropic viral vector which infects cells of the central nervous system of the mammal, said vector containing a selected DNA sequence operatively linked to a LAT promoter so that said selected DNA sequence is stably expressed for at least four months by infected central nervous system cells.

Claim 2 (canceled).

Claim 3 (original): The method of claim 1 wherein the selected DNA sequence encodes  $\beta$ -glucuronidase.

Claim 4 (original): The method of claim 1 wherein the selected DNA sequence encodes tyrosine hydroxylase.

Claim 5 (original): The method of claim 1 wherein the viral vector comprises an HSV vector.

Claim 6 (original): The method of claim 5 wherein the HSV vector comprises an HSV-1 strain.

Claim 7 (original): The method of claim 6 wherein the HSV-1 strain comprises strain 17.

Claim 8 (previously presented): A method of stably expressing  $\beta$ -glucuronidase in the brain of a mammal comprising administering to peripheral neuron cells of a mammal a neurotropic viral vector which infects cells of the brain of the mammal, said vector being an HSV-1 vector containing a DNA sequence encoding  $\beta$ -glucuronidase operatively

linked to a LAT promoter, so that the infected brain cells stably express  $\beta$ -glucuronidase.

Claim 9 (original): The method of claim 8 wherein the HSV-1 vector comprises HSV-1 strain 17.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **PENN-0065**  
Inventors: **Wolfe and Fraser**  
Serial No.: **08/393,066**  
Filing Date: **February 23, 1995**  
Examiner: **D. Crouch**  
Group Art Unit: **1804**  
Title: **Methods of Delivering Genes to the  
Central Nervous System of a Mammal**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Declaration of Laura M. Plunkett, Ph.D.

I, Laura M. Plunkett, hereby declare that:

1. I received a Bachelor's degree in Zoology from the University of Georgia and a Doctorate in Pharmacology from the University of Georgia, College of Pharmacy. I received a postdoctoral fellowship from the National Institute of General Medical Sciences, the Pharmacology Research Associate Training Program (PRAT Program), and performed my postdoctoral work at the National Institute of Mental Health. I am currently a manager in the Health Sciences group at ENVIRON International Corporation. Prior to joining ENVIRON, I was an Assistant Professor of Pharmacology in the Department of Pharmacology, College of Medicine, at the University of Arkansas for Medical Sciences. I also held an adjunct appointment to the Division of Toxicology. During my postdoctoral training and my years in academics, I performed basic research in pharmacology; my areas of expertise were cardiovascular and neuropharmacology, with an emphasis in

Attorney Docket No.:  
Inventors:  
Serial No.:  
Filing Date:  
Page 2

PENN-0065  
Wolfe and Fraser  
08/393,066  
February 23, 1995

neuropeptides and the neurochemical mechanisms involved in autonomic nervous system function. I also worked closely with a colleague who is a pharmacokineticist and have several publications relating to drug disposition. During my five years with ENVIRON, my consulting work has focused on U.S. Food and Drug Administration (FDA) regulation of drugs, biologics, and medical devices. I have assisted many clients in navigating the FDA approval process and am currently developing my own practice in Houston, Texas that emphasizes providing technical and regulatory support to small to medium-sized biotechnology companies. I have experience with both chemically-synthesized drug products as well as products of biotechnology. I consider myself an expert in pharmacology and toxicology and the FDA regulation of drug products of all types, regardless of the chemical nature of the substance. The details of my experience and a list of my publications are in my Curriculum Vitae that is attached as Exhibit 1.

2. I was asked by Dr. Jane Licata to assist her in the preparation of her response to the Patent Examiner concerning the method of delivering genes to the central nervous system of a mammal. She provided me with the specification as well as the Examiner's response dated September 13, 1996.

3. In order to demonstrate therapeutic utility it is necessary to demonstrate a pharmacological effect. By definition, a pharmacological effect is an effect of a drug or chemical agent that affects living processes (as defined in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, Section 1; Exhibit 2). Delivery of a gene to cells in the central nervous system (CNS) and subsequent expression of those genes is part of a living process, and, therefore, a pharmacological effect, just as

Attorney Docket No.: **PENN-0065**  
Inventors: **Wolfe and Fraser**  
Serial No.: **08/393,066**  
Filing Date: **February 23, 1995**  
Page 3

hormone release induced by a drug would be a pharmacologic effect. Therefore, the data described in the specification are demonstrative of therapeutic utility.

The fact that the specification describes a novel delivery system for a gene is an important consideration for the pharmacologist. This is because a therapy cannot be successful unless the target cells in the body are reached and effectively altered. Using the data described in the specification in Examples 4 and 5 (pages 25-26 of the specification), one of skill would have assurance that the invention would result in delivery of a gene to the target cells, the CNS, and be followed by expression of the gene in these target cells.

Further, the fact that the specification describes an experiment in animals in Examples 4 and 5 where the viral vector was administered through corneal abrasion indicates to one of skill that other peripheral routes of administration (intravenous injection for example) would also be suitable. This is because fundamental principles of pharmacokinetics indicate that although the rate and extent of absorption may be affected by route of administration, all routes will result in levels of the administered substance appearing in the systemic circulation and thus available for pharmacologic activity (*Goodman and Gilman's The Pharmacological Basis of Therapeutics*, pp. 5-11; Exhibit 3). Corneal abrasion is simply one route of peripheral administration.

4. It is a fundamental principle that pharmacological effect data are directly applicable to a demonstration of therapeutic utility. Such data are routinely requested and accepted by the FDA. If a substance shows good pharmacological activity *in vivo*

Attorney Docket No.: **PENN-0065**  
Inventors: **Wolfe and Fraser**  
Serial No.: **08/393,066**  
Filing Date: **February 23, 1995**  
Page 4

in animals, these data can be used for choosing a dosing strategy in humans. This is all part of the standard drug development process, has been so for two decades, and is not a novel concept. The information contained in the specification provides such data that would be used, in conjunction with general knowledge about the physiological system to be manipulated, to establish a strategy for use of such a delivery system in humans.

Finally, there is an important difference between therapeutic utility and therapeutic effect or benefit. *In vivo* animal data provide information on utility. The therapeutic effect or benefit of a treatment strategy, however, is the standard applied in the drug approval process which is handled by the FDA.

5. The Examiner asserts that the data described in a paper by Dobson et al. (1989) teaches delivery of a gene to the CNS of mice. Careful review of this paper, however, demonstrates that the authors describe only peripheral nervous system delivery. The spinal ganglia that are shown to have taken up the viral vector are actually located outside the CNS (Figure 5 in Dobson et al. 1989). The CNS is comprised exclusively of the brain and spinal cord. Spinal ganglia are located outside the CNS (see discussion in Landsberg, L. And J.B. Young, 1994, *Harrison's Principles of Internal Medicine*, pp. 412-413; Exhibit 4). The CNS is protected from exposure to foreign compounds (such as viruses) by the blood-brain barrier, a series of tight junctions at capillaries within the CNS (pg. 487 in *Harrison's Principles of Internal Medicine*; Exhibit 5). Therefore, in order for an agent to enter the CNS after injection into the peripheral system, it must be able to cross this barrier. Many therapeutic agents cannot cross this barrier and as a result are ineffective for treating clinical conditions that are caused by perturbations

Attorney Docket No.: **PENN-0065**  
Inventors: **Wolfe and Fraser**  
Serial No.: **08/393,066**  
Filing Date: **February 23, 1995**  
Page 5

in CNS function.

As a result, the fact that someone has shown the ability of a viral vector to infect cells in the peripheral nervous system (as in Dobson et al. 1989) would not imply to one of skill that that same vector would infect and successfully express genes in cells of the CNS. A pharmacologist would be convinced by data such as is seen in the specification (Examples 4 and 5) that the subject of the invention is capable of CNS infection and successful gene expression in a mammal.

*I hereby declare that all statements herein of my own knowledge are true and that all statements made on information or belief are believed to be true; and further that those statements were made with the knowledge that willful statements and the like so made are punishable by fine or by imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the application, any patent issuing thereupon, or any patent to which this verified statement is directed.*

12/12/96  
Date

Laura M. Plunkett

Laura M. Plunkett

# Adenovirus-Mediated Cytokine Gene Transfer at Tissue Sites

## Overexpression of IL-6 Induces Lymphocytic Hyperplasia in the Lung<sup>1</sup>

Zhou Xing,\* Todd Braciak,\* Manel Jordana,\* Kenneth Croitoru,<sup>†</sup> Frank L. Graham,<sup>‡</sup> and Jack Gauldie<sup>2\*</sup>

Molecular Virology and Immunology Program, \*Departments of Pathology, <sup>†</sup>Medicine and <sup>‡</sup>Biology, McMaster University, Hamilton, Ontario, Canada

The biologic function of cytokines may be best studied in the context of a defined tissue site. To establish a model for studying the function of IL-6 at local tissue sites, we targeted the IL-6 transgene into the bronchial epithelium in the lung of Sprague-Dawley rats by intratracheal administration of a recombinant human type 5 adenovirus with rat IL-6 cDNA incorporated into the E3 region of the viral genome. This approach led to a highly compartmentalized overexpression of the IL-6 transgene and production of bioactive protein within the lung for about 7 days post-infection. Associated with this overexpression of IL-6 was the development of profound local lymphocytic hyperplasia around day 7, characterized by the dramatic expansion of bronchial associated lymphoid aggregates and massive lymphocytic infiltration in the pulmonary parenchyma. Concurrently, there were strikingly increased numbers of lymphocytes in bronchoalveolar lavage fluids. The majority of these lymphocytes were found to be CD3<sup>+</sup>CD8<sup>+</sup> cytotoxic T and CD3<sup>+</sup>CD4<sup>+</sup> helper T cells with the remaining being primarily a small number of CD45R<sup>+</sup> B cells. In addition, there was moderate bronchial and alveolar epithelial hyperplasia associated with lymphocytic hyperplasia. However, all of these changes subsided concomitant with the decrease in IL-6 expression and the lung seemed normal at 12 to 14 days post-infection. Thus, our study provides a tissue-specific transient transgene model for investigating cytokine functions *in vivo* and demonstrates that IL-6 has a profound stimulatory effect on the local lymphoid tissue in the lung. *The Journal of Immunology*, 1994, 153: 4059.

**C**ytokines are essential soluble signals that mediate the mutual communication between cells in host defense and immune systems and may potentially be used as therapeutic agents for certain diseases such as malignancies (1). However, our knowledge concerning the biologic function of a given cytokine has mostly come from *in vitro* experiments. Apparently, the precise dissection of the biologic function of cytokines requires investigation in the context of a specific tissue site (2). Although the *in vivo* delivery of recombinant cytokines represents one such approach, it may not completely mimic the real *in vivo* situation of inflammation in which cytokines are produced locally within the affected tissue in a continuous

fashion and at high concentrations because of limited sources, limited access to interstitial tissue compartments, and fast degradation. In addition to transgenic models, viral-mediated transient cytokine transgene models have recently proven to be of great potential for investigating the *in vivo* function of cytokines (3). This approach closely mimics what may happen during the tissue response to insult by targeting the transgene to tissue cells resulting in high and continuing local expression for a prolonged but transient period. In addition, because viral vectors serve as a vehicle for delivering heterologous genes, they also provide valuable therapeutic potential in the context of the function of cytokines studied.

Human adenoviral vectors possess a number of advantages over other viral vectors including efficient infectivity, high level of expression of the transgene, ease of propagating high titers of virus, nondependence on target cellular DNA replication, and no or very low incorporation of viral DNA into the host genome (4-6). In addition, although human adenoviruses can infect a variety of cell types across many species,

Received for publication May 5, 1994. Accepted for publication July 29, 1994.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This study was supported by the Medical Research Council of Canada.

<sup>2</sup> Address correspondence and reprint requests to Dr. Jack Gauldie, Room 2N16, Health Sciences Centre, Department of Pathology, McMaster University, Hamilton, Ontario L8N 3Z5, Canada.

most of them display natural tropism for the respiratory epithelium (4, 7, 8). This feature makes them considerably attractive to studies aimed at investigating biologic functions of a cytokine in the lung.

IL-6 is a cytokine known to play an important role in host defense and immune mechanisms through induction of acute phase proteins and affecting B/T cell differentiation and proliferation (9). However, the effect of IL-6 at local tissue sites, particularly in the lung, still remains largely unclear. Although several recent studies with the use of skin- or brain-specific transgenic models (10, 11) or recombinant retroviral-mediated gene transfer to bone marrow cells (12, 13) have provided some insights into IL-6 functions at tissue sites, there is minimal information available on transgene models or adenoviral-mediated transgene approaches established to elucidate the *in vivo* function of cytokines including IL-6 in the lung.

We have previously shown the construction of recombinant human type 5 adenoviruses (Ad5)<sup>3</sup> expressing murine and rat IL-6 genes and the systemic effect of overexpressed IL-6 after i.p. administration of the recombinant vector in mice (14). In the current study, we have used Ad5rIL-6 to establish a transient transgene model in the rat to study IL-6 activities in the lung. Our data demonstrate that IL-6 transgene can be efficiently transferred into and highly expressed by the bronchial epithelium in the lung of Sprague-Dawley rats. Upon release, the biologically active IL-6 is largely confined within the lung, leading to a severe and reversible expansion of bronchial associated lymphoid aggregates with marked lymphocytic infiltration composed mainly of cytotoxic T cells along with helper T and B cells. Thus, our data not only extend the previous *in vitro* findings by demonstrating the potent effect of IL-6 on the local lymphoid tissue but also provide a tissue-specific transgene model system for studying cytokine functions in adult normal animals.

## Materials and Methods

### Recombinant adenovirus vectors

The recombinant human type 5 adenovirus with rat IL-6 cDNA incorporated in the E3 region of the viral genome (Ad5rIL-6) has been previously constructed and well characterized *in vitro* (14). This recombinant virus possesses the SV40 promoter and polyadenylation signal sequences, upstream and downstream of the inserted IL-6 cDNA, respectively. The recombinant human type 5 adenovirus with *Escherichia coli*  $\beta$ -galactosidase cDNA (Ad5LacZ) in the E3 region was constructed in a similar fashion (15). High titers of viral constructs were generated as previously described (5). Virus purified by CsCl gradient centrifugation was dialyzed thoroughly against four changes of autoclaved Tris-HCl buffer, pH 7.4, containing 10% glycerol, aliquoted, and stored at -75°C until use.

<sup>3</sup> Abbreviations used in this paper: Ad5, human type 5 adenoviruses; Ad5rIL-6, recombinant human type 5 adenovirus with rat IL-6 cDNA incorporated in the E3 region of the viral genome; pfu, plaque-forming units; Ad5LacZ, recombinant human type 5 adenovirus with *Escherichia coli*  $\beta$ -galactosidase cDNA; BAL, bronchoalveolar lavage; LacZ,  $\beta$ -galactosidase; CPI, cysteine proteinase inhibitor.

### Animals and establishment of viral infection in the lung

Sprague-Dawley male rats weighing 280 to 340 g (Charles River Laboratories, Ottawa, Canada) were used throughout the study. Ad5rIL-6 or Ad5LacZ as control was diluted, before use, to a concentration of  $2 \times 10^8$  plaque-forming units (pfu) with sterile endotoxin-free PBS, pH 7.4, in a final volume of 300  $\mu$ l. This infectious dose of  $2 \times 10^8$  pfu was used throughout the study on the basis of a dose-response experiment in which  $2 \times 10^8$  pfu of Ad5rIL-6 was shown to be a dosage that resulted in minimal immediate inflammatory responses but significant levels of IL-6 protein production in the lung by 24 h. Viral infection of the lung was established by intratracheal instillation of 300  $\mu$ l/rat of diluted Ad5LacZ or Ad5rIL-6 by using a standard procedure as previously described (16). PBS (300  $\mu$ l) alone with the same amount of glycerol present in the diluted virus samples had minimal effect on tissue responses in the lung.

### Serum collection and bronchoalveolar lavage

At the end of 0.5, 1, 2, 3, 5, 7, and 12 days after infection, rats were anesthetized and blood samples were drawn from the abdominal aorta. Sera were collected by centrifuging clotted blood samples at 2000 rpm for 10 min; the sera were stored at -20°C. Bronchoalveolar lavage (BAL) was performed as previously described (17) with minor modifications. A total of 30 ml warm PBS was used for each rat. The first 3 ml of PBS was instilled into lungs, recovered and left on ice, and five aliquots of the rest of PBS were separately instilled, recovered, and pooled. These two BAL fluids were spun at 1000 rpm at 4°C for 8 min. The supernatant from the first 3 ml of BAL was saved and stored at -20°C for IL-6 and cysteine proteinase inhibitor assays. The resulting two pellets were resuspended and pooled in 5 ml of PBS for total and differential cell counting. Differential cell counting was performed with Diff-Quik-stained cytocentrifuge slides from BAL samples, and a minimum of 350 to 450 cells were randomly counted on each cytocentrifuge slide.

### Histochemical localization of $\beta$ -galactosidase (LacZ) product

Histochemical staining for LacZ protein expression in the tissue was performed after a procedure described by Mastrangeli et al. (7) with minor modifications. Briefly, at 24 h after infection, the lungs were fixed by intratracheal perfusion at a pressure of 50 cm H<sub>2</sub>O with 2% formaldehyde containing 0.2% glutaraldehyde in PBS, at 4°C for 1 h. The fixative was poured out, and the lungs were rinsed twice by intratracheal instillation of 3 ml PBS and stained by intratracheal perfusion of the staining solution containing 5 mM K<sub>4</sub>Fe(CN)<sub>6</sub> (Sigma Chemical Co., St. Louis, MO), 5 mM K<sub>3</sub>Fe<sub>5</sub>(CN)<sub>6</sub> (Sigma Chemical Co.), 2 mM MgCl<sub>2</sub>, and 0.5 mg/ml of the X-gal stain (5-bromo-4-chloro-3-indolyl- $\beta$ -D-glucopyranoside; Boehringer Mannheim Corp., Indianapolis, IN) at 37°C overnight. The stained lung tissues were then paraffin-embedded, sectioned, and counterstained with nuclear red fast.

### IL-6 bioassay and rocket electrophoresis analysis for cysteine proteinase inhibitor (CPI)

IL-6 bioactivity in BAL and serum samples was measured by a modified B9 hybridoma growth factor assay (18) and the level of acute phase protein CPI in serum was measured by rocket electrophoresis as previously described (14). Briefly, samples were subjected to electrophoresis through a 1% agarose gel containing anti-CPI (150  $\mu$ l/12.5 ml gel) overnight at 60 V. After staining and destaining, amounts of CPI were determined according to the heights of protein peaks against a standard curve of purified protein.

### IL-6 mRNA expression by Northern blot hybridization

Expression of IL-6 mRNA in lung tissues after infection with Ad5rIL-6 virus was analyzed by Northern blot hybridization. Routinely, the left lung was fixed by perfusion with 4% paraformaldehyde for histology whereas the other lung was snap-frozen in liquid nitrogen for total tissue

RNA extraction. Total tissue RNA extraction and Northern blot hybridization were performed as previously described (18). The rat IL-6 cDNA probe used was a 700-bp *Pst*I fragment of PTZ 19R (19).

#### IL-6 mRNA localization by *in situ* hybridization

IL-6 mRNA in the bronchial epithelium of rats infected with Ad5rIL-6 was localized by using *in situ* hybridization techniques as previously described (20), except that after deparaffinization and rehydration, lung sections were pre-treated with 5  $\mu$ g/ml proteinase K at 37°C for 15 min before treatment with 0.25% acetic anhydride. Hybridization was performed by using the same IL-6 cDNA probe used for Northern analysis. As controls, hybridization of Ad5LacZ-infected lung tissues with an IL-6 cDNA probe and hybridization of Ad5rIL-6-infected lung tissues with a control DNA probe (a 0.5-kb fragment from a DNA ladder) (Life Technologies, Inc., Gaithersburg, MD), were performed in parallel. Slides coated with Kodak NTB-2 emulsion were autoradiographed at 4°C for 16 days before development.

#### Determination of lymphocyte subsets by FACS analysis

Total BAL cells from rat lungs at day 7 after infection with Ad5LacZ or Ad5rIL-6, were isolated as described above and washed with PBS containing 0.2% BSA and 0.1% sodium azide. Cell staining for FACS analysis was conducted as previously described (21). Briefly, for T lymphocyte phenotyping, aliquots of  $10^6$  cells were stained with biotin-conjugated mouse anti-rat CD3 mAbs (clone G4.18) for 30 min at 4°C, washed, and then stained with streptavidin PerCP, PE-conjugated mouse anti-rat CD4 (clone OX-35), or FITC-conjugated mouse anti-rat CD8a (clone OX-8) mAbs. To identify B lymphocytes, cells were directly stained with FITC-conjugated mouse anti-CD45R mAbs (clone HIS24). This mAb reacts specifically with a pan-B cell Ag (22). The optimal concentrations of various Abs for FACS staining were determined by staining normal rat splenocytes at serial concentrations of each Ab. The negative control Abs included anti-human biotin-CD8, PE-CD2, and FITC-CD3. The above Abs and PerCP were purchased from PharMingen, San Diego, CA and Becton Dickinson, San Jose, CA, respectively. After staining, samples were fixed with 1% paraformaldehyde and analyzed on a FACScan flow cytometer focusing on the lymphocyte cluster (Becton Dickinson).


## Results

#### Demonstration of viral infection by *in situ* staining of LacZ

Because Sprague-Dawley rats were a strain that had not been extensively used for the studies on adenovirus-mediated gene transfer in the lung, we first evaluated the establishment of infection at 24 h after intratracheal instillation of Ad5LacZ by examining the distribution and the cellular localization of LacZ in the lung. Grossly, the histochemically stained LacZ product was found all over on the surface of lungs and throughout serial slices of lungs (data not shown). Microscopic examination of thin tissue sections confirmed the wide distribution of LacZ staining in both right and left lungs. The major cellular sites of infection by Ad5LacZ were epithelial cells of small and respiratory bronchioles as well as of alveoli in the immediate vicinity (Fig. 1). No staining for LacZ was found in lung tissues infected with Ad5rIL-6.


#### IL-6 mRNA expression post-IL-6 cDNA transfer in the lung

Having tested the feasibility of the model, the intensity and duration of expression of transferred IL-6 cDNA in the



**FIGURE 1.** Demonstration of viral infection in the bronchial epithelium by *in situ* staining of  $\beta$ -galactosidase (LacZ) in the lung. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6 for 24 h, and the lungs were stained for LacZ by histochemistry. The blue staining identifies LacZ. **A:** Ad5LacZ-infected lung ( $\times 100$ ). **B:** Ad5LacZ-infected lung ( $\times 250$ ). **C:** Ad5rIL-6-infected lung ( $\times 120$ ). Solid arrows: some of the bronchiolar epithelial cells positive for LacZ. Open arrows: some of the alveolar epithelial cells positive for LacZ.

lungs were analyzed by Northern blot hybridization at different times post-infection with Ad5rIL-6. Figure 2 shows that transcripts for IL-6 were strongly overexpressed in total lung tissue after infection with Ad5rIL-6 and that these mRNA species transcribed from exogenously virally transferred IL-6 cDNA were distinguishable from the endogenous IL-6 message by their differences in size. Although LPS induced an endogenous IL-6 message with a




**FIGURE 2.** Kinetics of IL-6 transgene expression in total lung tissues. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6 for 0.5, 1, 3, and 7 days and total lung tissues were subjected to RNA extraction and Northern hybridization. The endogenous IL-6 message in total rat lung tissue induced by LPS challenge for 6 h serves as a size marker. The equal input of total RNA samples is indicated by 28S rRNA shown below.

minor 2.4-kb band and a major 1.3-kb band, mRNAs from Ad5rIL-6 seemed to consist of two bands with higher m.w. than the endogenous ones (about 2.8 kb and 2.0 kb, respectively). The IL-6 message increased as early as 12 h and was maximal for at least 3 days after infection with Ad5rIL-6. Significant expression was still seen up to day 7. In contrast, there was no significant IL-6 message detected in lungs infected with the control Ad5LacZ virus.


Because the bronchial epithelium was the major site for adenoviral incorporation as shown by LacZ staining in our model, it was very likely a cellular source for high expression of IL-6 mRNA observed by Northern analysis. To verify this, tissue sections from lungs after 3 days of infection with Ad5rIL-6 or Ad5LacZ were hybridized in situ with a cDNA probe for rat IL-6 or with a similar-sized DNA fragment as a control probe, and cellular localization of IL-6 mRNA was examined. Figure 3 shows that only bronchial epithelial cells in the lungs infected with Ad5rIL-6 but not with Ad5LacZ localized the message for IL-6 and that there was no message localized to bronchial epithelial cells in Ad5rIL-6-infected lungs when tissue was hybridized with the control DNA probe.

#### *Bioactive IL-6 protein secretion post-IL-6 cDNA transfer in the lung*

To determine whether the biologically active IL-6 protein was released as a result of overexpression of IL-6 message, B9 hybridoma growth assay was performed to analyze IL-6 content in BAL samples from rats infected with



**FIGURE 3.** IL-6 mRNA localization in the bronchial epithelium by in situ hybridization. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6 for 3 days and lung tissue sections were processed for in situ hybridization. *A*, Ad5rIL-6-infected lung hybridized with the rat IL-6 cDNA probe ( $\times 250$ ). *B*, Ad5rIL-6-infected lung hybridized with the control DNA probe ( $\times 250$ ). *C*, Ad5LacZ-infected lung hybridized with the rat IL-6 cDNA probe ( $\times 250$ ). Arrows: bronchial cells positive for IL-6 message.



**FIGURE 4.** Kinetics of bioactive IL-6 protein content in BAL and serum by B9 hybridoma growth assay. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6, and BAL (top) and serum (bottom) samples were collected and assayed for IL-6 content at days 0.5, 1, 3, 5, and 7 after infection. Results for 1, 3, and 5 days represent mean  $\pm$  SEM of samples from more than three rats.

Ad5rIL-6. Consistent with the kinetics of IL-6 mRNA expression, significant secretion of IL-6 was detected in BAL over a period of at least 7 days with peak secretion seen around day 3 after infection by Ad5rIL-6 (Fig. 4A). In contrast, only minimal amounts of IL-6 were present in BAL of rats infected with the control virus. To determine the degree to which IL-6 bioactivity was confined to the lung, serum samples were also assayed for IL-6. Figure 4B shows that only very low amounts of IL-6 appeared in sera of rats infected intratracheally with Ad5rIL-6 but the kinetics were similar to those found in BAL fluids.

#### IL-6 induction of CPI in serum

To determine whether IL-6 that "spilled" from the lung into serum was functionally active in inducing the produc-

tion of acute phase proteins by the liver, one of the major acute phase proteins of rat, CPI, was measured with serum samples collected from infected rats. Significantly greater amounts of serum CPI were detected in sera of rats after Ad5rIL-6 viral infection as compared with infection with Ad5LacZ, on the average, 6.7, 11.7, and 17 mg/ml vs 2.3, 3.0, and 5.2 mg/ml at days 1, 2, and 3, respectively.


#### Local effects of IL-6 overexpression on total lymphocyte number in BAL

To investigate whether the over-expressed IL-6 had any local functional effects in the lung, the kinetics of differential cell counts in BAL fluids collected from rats at different times after intratracheal infection were examined. As shown in Figure 5, at 12 h after infection with the control virus or Ad5rIL-6, there was minimal accumulation of leukocytes other than the resident alveolar macrophages. Thereafter, an early neutrophilic response (up to 20% neutrophils) was noticed in BAL of rats infected with both viruses. This was accompanied by mildly increasing numbers of monocytes and lymphocytes. In this regard, no significant differences were observed up to day 5, between the control virus- and Ad5rIL-6-infected rats. However, although after day 5 the recruited inflammatory cells including lymphocytes began subsiding toward basal levels in BAL of rats infected with Ad5LacZ, there was a drastically increased number of total lymphocytes in BAL of rats infected with Ad5rIL-6; total lymphocytes were observed to be maximal at day 7 for Ad5rIL-6-infected rats, with  $20 \times 10^6$  lymphocytes as opposed to  $3 \times 10^6$ /BAL in Ad5LacZ. Moderate increases in the total number of alveolar macrophages and neutrophils accompanied lymphocytic expansion. By day 12, however, the number of total lymphocytes significantly declined, and by day 14, it was further decreased, close to the basal line (data not shown). To further confirm the IL-6-induced lymphocytic expansion observed at day 7, additional rats were infected, and BAL cell differentials were analyzed at day 7. On the average,  $4.8 \times 10^6$  of total BAL cells were recovered from each control virus-infected rat, with  $2.4 \times 10^6$  being alveolar macrophages and  $1.8 \times 10^6$  being lymphocytes, whereas  $35.7 \times 10^6$  of total BAL cells were recovered from each Ad5rIL-6-infected rat, with  $21.3 \times 10^6$  being lymphocytes (Table I).

#### Local effects of IL-6 overexpression on lymphocyte subsets in BAL

We were then interested in determining whether IL-6 had any effects on the accumulation of a particular subtype of lymphocytes. To address this, rats were intratracheally infected with either the control virus or Ad5rIL-6 for 7 days and the lymphocytes in the subsequent BAL cells were subtyped by FACS analysis using specific mAbs against a pan-B cell Ag CD45R, a TCR component CD3, a helper T cell marker CD4, and a cytotoxic T cell marker CD8a.

**FIGURE 5.** Kinetics of neutrophils (PMN), monocytes (MONO), lymphocytes (LC), and alveolar macrophages (AM) in BAL. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6 for different periods of time and BAL fluids were collected and analyzed for differential cell counts. At day 0, about  $2 \times 10^6$  total cells were recovered and more than 96% of them were AM in BAL of rats infected with Ad5LacZ or Ad5rIL-6. Results represent means of samples from two rats for each time point.



**Table I.** Cellular components in day 7 BAL<sup>a</sup>

Total Cells	AM	PMN	MONO	LC	
Ad5LacZ	4.8 ± 2.7	2.4 ± 0.6	0.4 ± 0.4	0.2 ± 0.2	1.8 ± 1.7
Ad5rIL-6	35.7 ± 8.5	7.5 ± 2.7	5.3 ± 2.8	1.7 ± 0.4	21.3 ± 4.1


<sup>a</sup> Rats were infected with Ad5LacZ or Ad5rIL-6 for 7 days and the number ( $\times 10^6$ ) of alveolar macrophages (AM), neutrophils (PMN), monocytes (MONO), or lymphocytes (LC) in BAL fluids was determined on Diff-Quik-stained cytopsins. Results represent mean ± SD from six and seven rats infected with Ad5LacZ or Ad5rIL-6, respectively.

Similar percentages of B cells and helper and cytotoxic T cells were found in BAL lymphocytes from both Ad5LacZ and Ad5rIL-6 infected rats (Fig. 6). Among the lymphocyte population analyzed, a small percentage were CD45R<sup>+</sup> cells (2 to 4%), about 30% were CD3<sup>+</sup>CD4<sup>+</sup> cells, and 47% were CD3<sup>+</sup>CD8<sup>+</sup> cells. However, the absolute number of each lymphocyte subset increased dramatically in BAL of rats with local overexpression of IL-6 (Table II), as a result of marked expansion of total lymphocyte numbers. On the average, BAL of the Ad5rIL-6-infected rat contained about 8, 8, and 10 times as many B cells, CD3<sup>+</sup>CD4<sup>+</sup> T, and CD3<sup>+</sup>CD8<sup>+</sup> T cells, respectively, as those in BAL of the control virus-infected rat. It was also noted that the ratio of CD4<sup>+</sup> to CD8<sup>+</sup> cells remained similar between the control virus- and Ad5rIL-6-infected animals.

#### *Local effects of IL-6 overexpression on bronchial lymphoid tissue and histopathology in the lung*

To reveal the potential origin of markedly increased lymphocytes in BAL and the histopathologic consequences after IL-6 overexpression, rat lungs at different time points

after infection were fixed by perfusion without lavage and processed for histopathologic examination. Before day 5, there was a mild to moderate inflammatory response in the parenchyma of lungs infected with Ad5LacZ or Ad5rIL-6, marked by hyperemia and peribronchial or perivascular and/or interstitial neutrophilic and mononuclear cell infiltration. Up to day 5, similar although greater enlargement of the bronchial associated lymphoid tissue was observed in lungs infected with Ad5rIL-6. However, by day 7, although the moderate interstitial mononuclear response described above remained in control virus-infected lungs with mild development of bronchial epithelial hyperplasia (Fig. 7, A and B), both alveolar and interstitial spaces of lungs infected with Ad5rIL-6 were typified by profound lymphocytic hyperplasia. Most noticeably, the local bronchial associated lymphoid tissues were seen to be undergoing extreme expansion such that in many instances, they pushed their way from the submucosa into the epithelium, forming intrabronchial protrusions (Fig. 7C). Meanwhile, there was pronounced and diffuse lymphocytic infiltration throughout the lung (Fig. 7, D and E). In addition, abundant clefts were seen inside the bronchial lumen as a result of apparent bronchial epithelial hyperplasia (Fig. 7C). In some areas, hyperplasia of type II alveolar epithelial cells was manifest (Fig. 7D). By day 12, however, although some moderate enlargement of lymphoid tissues was still present (Fig. 7F), the magnitude of lymphocytic response dramatically decreased (marked by the clearance of interstitial lymphocytic infiltrates and the disappearance of hyperplastic bronchial and alveolar epithelial cells) and the lung tissue seemed to be close to normal (Fig. 7, F and G). The residual reactive germinal center noted in Figure 7G



**FIGURE 6.** Lymphocyte subsets in BAL by FACS analysis. Rats were intratracheally infected with Ad5LacZ or Ad5rIL-6 for 7 days and lymphocytes in total BAL cells were subtyped by FACS staining by using monoclonal anti-CD45R, anti-CD3, anti-CD4, and anti-CD8 Abs. The figure is representative of one of two independent experiments.

Table II. Lymphocyte subsets in BAL<sup>a</sup>

	CD45R <sup>+</sup>	CD3 <sup>+</sup>	CD3 <sup>+</sup> CD4 <sup>+</sup>	CD3 <sup>+</sup> CD8 <sup>+</sup>	Ratio (CD4 <sup>+</sup> /CD8 <sup>+</sup> )
<b>Ad5LacZ</b>					
Expt. 1	0.05	1.0	0.39	0.60	0.64
Expt. 2	0.06	2.6	1.09	1.48	0.73
<b>Ad5rIL-6</b>					
Expt. 1	0.5	14.8	5.67	8.57	0.66
Expt. 2	0.28	17.3	5.43	11.47	0.47

<sup>a</sup> Lymphocytes in total BAL cells from rats infected with Ad5LacZ or Ad5rIL-6 for 7 days were subtyped by FACS analysis. Results are expressed as the number ( $\times 10^6$ ) of cells positive for the surface marker(s) in BAL of each rat from two independent experiments.

was occasionally seen in the lung of Ad5rIL-6-infected but not Ad5LacZ-infected or uninfected rats.

## Discussion


In this study, we have shown the establishment of an adenoviral transgene model for exploring the local functions of overexpression of IL-6 in the lung. By intratracheal administration of a human adenoviral vector with rat IL-6 cDNA incorporated in the E3 region of the viral genome, IL-6 cDNA was targeted to the lining cells, mainly bronchial epithelial cells, of the respiratory tract in rats, with bioactive IL-6 protein being highly expressed and localized within the lung for at least 7 days after infection. Associated with overexpression of IL-6 were severely expanded local bronchial lymphoid tissues with massive lymphocytic infiltration and hyperplasia of bronchial and alveolar epithelial cells, observed around day 7. Consistent with histologic lymphocytic hyperplasia in the lung, there were dramatically increased numbers of lymphocytes recovered in BAL, composed mainly of cytotoxic T cells

along with helper T and B cells at day 7. These lymphocytic and associated lung tissue responses to IL-6 overexpression returned largely to normal after 12 to 14 days post-infection.

This adenoviral IL-6 transgene lung model was established by using Sprague-Dawley rats, whereas previously reported studies with the use of adenoviral vectors in the lung have mainly employed cotton rats (7, 23, 24). Our results demonstrate an efficacy of adenovirus-mediated gene transfer to the bronchial epithelium similar to that in cotton rats (7), but in our model, we also show that some alveolar epithelial cells can be infected. Thus, Sprague-Dawley rats may represent a suitable, easily available and perhaps more economical source of animals for studying cytokine functions in the lung.

We demonstrate that the IL-6 transgene product is highly expressed and compartmentalized within the lung. This is in agreement with the fact that intratracheally administered adenoviruses remain almost exclusively within the lung as shown by us (14) and others (24). Thus, the very low levels of IL-6 detected in serum were most likely "spilled" from the lung. The high compartmentalization of the transgene product adds another unique feature to this lung model of adenovirus-mediated cytokine gene transfer.

Significant release of bioactive IL-6 protein could be detected in BAL for about 7 days after infection with Ad5rIL-6. This local elaboration of IL-6 in lung tissue seemed to sustain somewhat longer than the elaboration that we previously detected in mouse serum after i.p. administration of the same vector expressing murine IL-6 (14). The mechanism underlying the transient nature of expression is unclear but may be partly determined by the type of cells infected and the fact that adenoviruses rarely



incorporate into the host cell genome. This seems to distinguish the adenoviral vector approach from a previously described retroviral one in which a lethal myeloproliferative disease resulted from a much more prolonged overexpression of IL-6 after transplantation with the recombinant retroviral IL-6-infected bone marrow cells (13). In addition, the transient nature of IL-6 expression in the lung may also relate to the replicative state of the virus. Although the human viral vector with the intact E1 region we used is in theory capable of replication, only very low levels of replication occur in rodent cells *in vitro*. Thus, it remains unclear whether this adenoviral vector replicates to a significant extent in rats *in vivo*. The kinetic expression of IL-6 mRNA subsequent to Ad5rIL-6 introduction correlated well with that of IL-6 protein release into BAL. By day 7, a significant but decreased message was still detected in Ad5rIL-6-infected lung tissue. The alteration in size of mRNAs different from endogenous species likely resulted from the alternative start sites for transcription. In this regard, recent evidence has suggested that expression of the cDNA inserted in the E3 region may also be driven by promoters such as the major late promoter further upstream of the SV40 promoter present immediately in front of the insert (25). The changes in size of mRNAs have been observed in other studies with the use of transgene approaches (23, 26).

Having characterized the model, we explored its usefulness in studying IL-6 function *in vivo*. Systematically, we found that even the low serum levels of IL-6 leaked from the lung could act on the liver, increasing production of CPI. Locally, overexpressed IL-6 exerted a profound effect on local lymphoid tissues resulting in marked expansion of bronchial associated lymphoid aggregates. This was accompanied by diffuse lymphocytic infiltrates in the pulmonary parenchyma, the majority of which were cytotoxic T cells along with helper T and B cells, as shown by FACS analysis.

Upon close histopathologic examination of infected lung tissues, it was noted that there was no marked lymphocytic hyperplasia, neither lymphoid tissue expansion nor diffuse parenchymal lymphocytic accumulation, observed until about day 7 after infection with Ad5rIL-6. The kinetic pattern of lymphoid expansion in the tissue was in fact echoed by increases in the number of total lymphocytes recovered in BAL fluids from Ad5rIL-6-infected rats, suggesting that the tissue infiltrating lymphocytes were at least in part local lymphoid tissue derived. Before day 7, there was no substantial differences in the degree of accumulation of neutrophils, monocytes, macrophages, and lymphocytes in BAL observed between control virus-

and Ad5rIL-6-treated rats. Together, these indicate a cell type-specific and time-dependent effect from overexpressed IL-6. In agreement with observations in the current study, we have previously shown that by day 7 after systemic (i.p.) administration of Ad5 mIL-6, mice developed splenomegaly as a result of local lymphoid expansion and lymphoid aggregates in the liver (14). Similar lymphocytic expansion in the spleen of naive mice was also noted in a study after continuing systemic administration of recombinant IL-6 for 4 days (27). These findings together with the current observation suggest that the effect of IL-6 on lymphoid tissues is also site-specific depending upon the route of IL-6 delivery or expression. In our studies, peak lymphoid hyperplasia in the lung occurred around the time (day 7) at which the primary immune response, particularly the specific T cell response, usually develops, implying that IL-6 induces the expansion of lymphoid tissues or cells perhaps partly by amplifying the specific immune response against viral Ags. Indeed, Mule et al. (28) have recently demonstrated that even systemically repeatedly administered recombinant IL-6 can result in regression of established lung micrometastases from immunogenic but not from nonimmunogenic tumors by elicitation of lymphocytic infiltration in the tumor and the surrounding lung tissue at days 6 and 8 after injection of tumor cells. Thus, our model demonstrates a potent effect on the local immune system reinforced by both locally overexpressed IL-6 and immunogenic viral Ags.

Consistent with our previous observation that splenomegaly and hepatic lymphocytic aggregates were seen at day 7 and subsided by about 14 days after i.p. administration of Ad5 mIL-6 (14), overexpression of IL-6 induced a reversible pronounced lymphocytic hyperplasia in the lung which recovered significantly by about day 12, probably because of the transient nature of IL-6 expression. There seemed to be some indications of damage to both bronchial and alveolar epithelial cells suggested by hyperplastic changes in these cells, which most likely represents functional consequences from marked lymphocytic hyperplasia because all of these alterations were concurrently observed around day 7. These pathologic changes in the bronchial and alveolar epithelia also noticeably disappeared by day 12 and the pulmonary tissues showed no signs of permanent damages such as fibrosis. We cannot, at this point, rule out some late reactions with fibrotic changes, but this is unlikely, given the nature and rapidity of the resolution to tissue pathology seen in this case. This

**FIGURE 7.** Representative microphotographs of lung histopathology in rats infected with Ad5LacZ or Ad5rIL-6. *A* and *B*: Ad5LacZ infection at day 7 (*A*,  $\times 100$ ; *B*,  $\times 120$ ). *C*, *D*, and *E*: Ad5rIL-6 infection at day 7 (*C*,  $\times 40$ ; *D* and *E*,  $\times 120$ ). *F* and *G*: Ad5rIL-6 infection at day 12 ( $\times 100$ ). Open arrows: bronchial epithelial clefts. Solid arrows: type II alveolar epithelial hyperplasia. BALA: bronchial-associated lymphoid aggregates; PVL: perivascular lymphocytic cuffs; DL: diffuse lymphocytic infiltration.

reversible nature of functional overexpression of the transgene by this approach has implications in evaluating the therapeutic value of IL-6.

Furthermore, overexpression of IL-6 induced proportional increases of major subsets of lymphocytes in the lung including cytotoxic and helper T and B cells. This is in agreement with *in vitro* findings that IL-6 has stimulating effects on proliferation and differentiation of both T and B cells (9). Systemically delivered recombinant IL-6 has also been shown to increase the number of both T and B cells in the spleen *in vivo* (27). We found that the majority of lymphocytes in BAL of Ad5rIL-6-infected rats were T cells (CD3<sup>+</sup>, 80%) among which 30% were helper T (CD3<sup>+</sup>CD4<sup>+</sup>) and 50% cytotoxic T cells (CD3<sup>+</sup>CD8<sup>+</sup>) with a ratio of T<sub>H</sub>/T<sub>C</sub> being about 2/3. The B cells (CD45R<sup>+</sup>) accounted only for about 3% of total lymphocytes in BAL. The remaining lymphocytes (about 20%) were probably killer T lymphocytes and "null" lymphocytes which cannot be conventionally typed as B or T cells in BAL (29). Although the proportion of total T vs B cells was not significantly altered in comparison to those found in BAL under physiologic conditions, the ratio of T<sub>H</sub>/T<sub>C</sub> seemed to be reversed compared with the normal 1.5 (29). This significantly increased proportion of cytotoxic T cells was unlikely a result of the effect of overexpressed IL-6 because a similar ratio of T<sub>H</sub>/T<sub>C</sub> was also found in the lymphocytes in BAL of the control virus-infected rats. Thus, it was likely a result of the response to viral infection. The increased proportion of cytotoxic T cells has been found in hypersensitivity pneumonitis (30) and some asthmatic conditions (31). These data suggest that overexpressed IL-6 has an unselective lymphocyte-expanding effect in the lung and that the predominant expansion of cytotoxic T cells by adenoviral IL-6 transgene approach may greatly favor responses that involve cytotoxic T cell-mediated cellular immunity.

In conclusion, in this study, we demonstrate the establishment of a model using adenovirus-mediated gene transfer to study the biologic function of cytokines at the local lung tissue site. Our data show that the IL-6 transgene can be expressed in high amounts within the lung and this overexpression causes a marked local lymphocytic expansion that is self-reversible in nature. This highly localized lymphocytic response driven by adenovirus-mediated overexpression of IL-6 may be potentially used to combat conditions such as cancer or infectious diseases.

### Acknowledgments

We thank Duncan Chong and Jane-Ann Schroeder, Xueya Feng, Darlene Steele-Norwood, and Mona Sabry for their invaluable technical assistance.

### References

1. Tepper, R. I., and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. *Hum. Gene Ther.* 5:153.
2. Nathan, C., and M. Sporn. 1991. Cytokines in context. *J. Cell Biol.* 113:981.
3. Ramshaw, I., J. Ruby, A. Ramsay, G. Ada, and G. Karupiah. 1992. Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections *in vivo*. *Immunol. Rev.* 127:157.
4. Roemer, K., and T. Friedmann. 1992. Concepts and strategies for human gene therapy. *Eur. J. Biochem.* 208:211.
5. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In *Methods in Molecular Biology*, Vol. 7: *Gene Transfer and Expression Protocols*. E. J. Murray and J. M. Walker, eds. Humana Press Inc., Clifton, NJ, pp. 109-127.
6. Kozarsky, K. F., and J. M. Wilson. 1993. Gene therapy: adenovirus vectors. *Curr. Opin. Genet. Dev.* 3:499.
7. Mastrangeli, A., C. Danel, M. A. Rosenfeld, L. Stratford-Perricaudet, M. Perricaudet, A. Pavirani, J.-P. Lecocq, and R. G. Crystal. 1993. Diversity of airway epithelial cell targets for *in vivo* recombinant adenovirus-mediated gene transfer. *J. Clin. Invest.* 91:225.
8. Rosenfeld, M. A., W. Siegfried, K. Yoshimura, K. Yoneyama, M. Fukayama, L. E. Stier, P. K. Paakkko, P. Gilardi, L. D. Stratford-Perricaudet, M. Perricaudet, S. Jallat, A. Pavirani, J.-P. Lecocq, and R. G. Crystal. 1991. Adenovirus-mediated transfer of a recombinant  $\alpha$ 1-antitrypsin gene to the lung epithelium *in vivo*. *Science* 252:431.
9. Cox, G., and J. Gauldie. 1992. Structure and function of IL-6. In *Cytokines in Health and Disease*. S. L. Kunkel and D. G. Remick, eds. Marcel Dekker, Inc., New York, p. 97.
10. Turksén, K., T. Kupper, L. Degenstein, I. Williams, and E. Fuchs. 1992. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. *Proc. Natl. Acad. Sci. USA* 89:5068.
11. Campbell, I. L., C. R. Abraham, E. Masliah, P. Kemper, J. D. Inglis, M. B. A. Oldstone, and L. Mucke. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. *Proc. Natl. Acad. Sci. USA* 90:10061.
12. Brandt, S. J., D. M. Bodine, C. E. Dunbar, and A. W. Nienhuis. 1990. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. *J. Clin. Invest.* 86:592.
13. Hawley, R. G., A. Z. C. Fong, B. F. Burns, and T. S. Hawley. 1992. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. *J. Exp. Med.* 176:1149.
14. Braciak, T. A., S. K. Mittal, F. L. Graham, C. D. Richards, and J. Gauldie. 1993. Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes: an approach to investigate *in vivo* cytokine function. *J. Immunol.* 151:5145.
15. Bett, A. J., L. Prevec, and F. L. Graham. 1993. Packaging capacity and stability of human adenovirus type 5 vectors. *J. Virol.* 67:5911.
16. Xing, Z., H. Kirpalani, D. Torry, M. Jordana, and J. Gauldie. 1993. Polymorphonuclear leukocytes as a significant source of tumor necrosis factor- $\alpha$  in endotoxin-challenged lung tissue. *Am. J. Pathol.* 143:1009.
17. Jordana, M., C. Richards, L. B. Iring, and J. Gauldie. 1987. Spontaneous *in vitro* release of alveolar macrophage cytokines after the intratracheal instillation of bleomycin in rats. *Am. Rev. Respir. Dis.* 137:1135.
18. Xing, Z., M. Jordana, T. Braciak, T. Ohtoshi, and J. Gauldie. 1993. Lipopolysaccharide induces expression of granulocyte/macrophage colony-stimulating factor, interleukin-8, and interleukin-6 in human nasal but not lung, fibroblasts: evidence for heterogeneity within the respiratory tract. *Am. J. Respir. Cell Mol. Biol.* 9:255.
19. Gauldie, J., W. Northemann, and G. H. Fey. 1990. IL-6 functions as an exocrine hormone in inflammation. *J. Immunol.* 144:3804.
20. Xing, Z., M. Jordana, H. Kirpalani, K. E. Driscoll, T. J. Schall, and J. Gauldie. 1994. Cytokine expression by neutrophils and macrophages *in vivo*: endotoxin induces tumor necrosis factor- $\alpha$ , macrophage inflammatory protein-2, interleukin-1 $\beta$  and interleukin-6 but not RANTES or transforming growth factor- $\beta$ 1 mRNA expression in acute lung inflammation. *Am. J. Respir. Cell Mol. Biol.* 10:148.
21. Croitoru, K., R. H. Stead, J. Bienenstock, G. Fulop, D. G. Harnish, L. D. Shultz, P. K. Jeffery, and P. B. Ernst. 1990. Presence of intestinal intraepithelial lymphocytes in mice with severe combined immunodeficiency disease. *Eur. J. Immunol.* 20:645.
22. Kroese, F. G. M., E. C. Butcher, P. A. Lalor, A. M. Stall, and L. A. Herzenberg. 1990. The rat B cell system: the anatomical localization

- of flow cytometry-defined B cell subpopulations. *Eur. J. Immunol.* 20:1527.
23. Rosenfeld, M. A., W. Siegfried, K. Yoshimura, K. Yoneyama, M. Fukayama, L. E. Stier, P. K. Paakkko, P. Gilardi, L. D. Stratford-Perricaudet, M. Perricaudet, W. B. Guggino, A. Pavirani, J.-P. Lecocq, and R. G. Crystal. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. *Cell* 68:143.
24. Zabner, J., D. M. Petersen, A. P. Puga, S. M. Graham, L. A. Couture, L. D. Keyes, M. J. Lukason, J. A. St. George, R. J. Gregory, A. E. Smith, and M. J. Welsh. 1994. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. *Nat. Genet.* 6:75.
25. Mittal, S. K., M. R. McDermott, D. C. Johnson, L. Prevec, and F. L. Graham. 1993. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. *Virus Res.* 28:67.
26. Whitsett, J. A., C. R. Dey, B. R. Stripp, K. A. Wikenheiser, J. C. Clark, S. E. Wert, R. J. Gregory, A. E. Smith, J. A. Cohn, J. M. Wilson, and J. Engelhardt. 1992. Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice. *Nat. Genet.* 2:13.
27. Puri, R. K., and P. Leland. 1992. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo. *Lymphokine Cytokine Res.* 11:133.
28. Mule, J. J., M. C. Custer, W. D. Travis, and S. A. Rosenberg. 1992. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. *J. Immunol.* 148:2622.
29. Reynolds, H. Y. 1987. Bronchoalveolar lavage. *Am. Rev. Respir. Dis.* 135:250.
30. Daniele, R. P., J. A. Elias, P. E. Epstein, and M. D. Rossman. 1985. Bronchoalveolar lavage: role in the pathogenesis, diagnosis, and management of interstitial lung disease. *Ann. Intern. Med.* 102:93.
31. Kemeny, D. M., D. Diaz-Sanchez, and B. J. Holmes. 1992. CD8<sup>+</sup> T cells in allergy. *Allergy* 47:12.

APPENDIX 4

# GOODMAN & GILMAN'S The PHARMACOLOGICAL BASIS OF THERAPEUTICS

Ninth Edition

McGraw-Hill  
HEALTH PROFESSIONS DIVISION

New York St. Louis San Francisco Auckland Bogotá Caracas Lisbon London Madrid  
Mexico City Milan Montreal New Delhi San Juan Singapore Sydney Tokyo Toronto

## C H A P T E R 5

# GENE-BASED THERAPY

*Stephen L. Eck and James M. Wilson*

*Advances in molecular and cellular biology have described the proteins that mediate many disease processes, while DNA technology provides ready access to the genes that control these events. The size, complexity, and cellular inaccessibility of these proteins make their delivery or modification by conventional pharmacological means impossible. Gene therapy overcomes these barriers by the selective introduction of recombinant DNA into tissues so that the biologically active proteins can be synthesized within the cells whose function is to be altered. As such, delivery of recombinant DNA has become a central issue in all gene therapy strategies. A variety of DNA delivery systems have been developed based on viral life cycle pathways, liposome encapsulation, direct injection, and complexation with carrier proteins. Although originally envisioned as a treatment for inherited single-gene defects, gene therapy has found applications in acquired illnesses such as cancer, cardiovascular and infectious diseases. This chapter provides an introduction to the therapeutic issues and current strategies being explored to apply gene therapy to this wide range of diseases.*

## SCOPE OF GENE THERAPY

Therapeutic gene transfer is not a new concept (Wolff and Lederberg, 1994). More than two decades before the first gene transfer took place in a clinical setting, Edward Tatum speculated: "We can even be somewhat optimistic on the long-range possibility of therapy by the isolation or design, synthesis, and introduction of new genes into defective cells of particular organs" (Tatum, 1966). The treatment of human disease by gene transfer originally was envisioned as a means to treat diseases arising from single-gene defects. Inherited diseases encompass a wide range of disorders wherein a defective gene leads to the failure to synthesize a particular protein or to the synthesis of an abnormal protein. In either event, the absence of the normal protein can lead to a variety of clinical manifestations depending on the structural or enzymatic role that protein normally plays in the cell. Such conditions range from mild disorders that require no treatment (e.g., color blindness) to life-threatening diseases (e.g., hemophilia, cystic fibrosis). These diverse diseases are, in general, inadequately treated by conventional pharmacological means. Therapy based on the replacement of the missing or defective protein (such as factor VIII for hemophilia, transfusions for sickle cell disease, and adenosine deaminase for severe combined immunodeficiency syndrome) is available for only a few of these disorders. Furthermore, these therapies

are only partially effective in ameliorating the manifestations of the disease and are accompanied by significant complications. For most genetic diseases, providing the missing protein in a therapeutic fashion is not feasible due to the complex and fragile nature of the protein and the need to deliver the protein to a specific subcellular location (i.e., cell surface expression, lysosomal localization, etc.). Transplantation of the major affected organ has been done in some instances (e.g., bone marrow transplantation for sickle cell disease, or liver transplantation for hyperlipidemias), but this also has severe limitations of organ availability and adverse consequences arising from the immune suppression required to prevent rejection of an allogeneic tissue.

Providing a normal copy of the defective gene to affected tissues would circumvent the problem of delivering complex proteins, as the protein could be synthesized within the cells using the normal cellular pathways. Although the defective gene is present in all cells of an individual with an inherited disorder, only a few tissues or organs actually express the gene and therefore are affected. Defects in genes that function in all cells of the body (so-called housekeeping genes) usually result in such severe abnormalities that embryonic development cannot occur. The limited number of tissues affected by most inherited disorders greatly simplifies the requirements for effective gene therapy, since a functional copy of the gene need be

provided only to those tissues that actually require it. The goal of gene therapy, therefore, is to genetically correct the defect in only part of the body. Since this type of therapy is designed not to alter the genetic structure of reproductive organs, it does not prevent the genetic disorder from being passed on to subsequent generations. It is envisioned, however, as a powerful tool to ameliorate or reverse the metabolic consequences in the treated individual. Targeting of the therapeutic gene to a specialized tissue is an area of tremendous interest in all applications of gene therapy. Furthermore, if the gene transfer can be targeted to the major affected organs, then side effects arising from ectopic gene expression in nontarget cells might be avoided. As with other pharmaceutical agents, cell-specific targeting has the advantage of decreasing the effective volume of distribution and the amount of gene transfer agent needed. Such cell-specific delivery systems are not yet available for either drugs or genetic material, but it can be reasonably expected that the explosion of interest in gene therapy will result in new methods that are applicable to the delivery of DNA and conventional pharmaceuticals alike. DNA delivery systems are being developed using a variety of chemical, physical, and biologic agents.

The earliest human gene transfer experiments began in 1989 with lymphocyte marking studies. While offering no therapeutic benefit, these initial studies showed that gene transfer could be safely carried out and provided insight into many of the technical difficulties of human gene transfer (Rosenberg *et al.*, 1990). Lymphocytes were likely targets for initial gene therapy attempts because they can be isolated easily and manipulated *ex vivo*. Thus, tissue targeting can be effected by physical removal and manipulation of the recipient cells, rather than by design of the gene delivery system, which has so far proved difficult. Lymphocytes were also attractive because they are the cellular locus of several inherited and acquired disorders (e.g., severe combined immunodeficiency, HIV infection, graft versus host disease, and a variety of malignancies). Furthermore, in addition to being readily isolated, lymphocytes may be expected to be long-lived on return to the recipient and therefore can potentially provide lasting benefits in chronic disorders. Thus, lymphocyte gene transfer provides an important model for gene therapy and continues to be developed for many disorders. In September 1990, the first human gene therapy trial with therapeutic potential began. The *ex vivo* gene transfer of adenosine deaminase (ADA) gene into the lymphocytes of a child with what is normally a lethal deficiency of this enzyme was carried out at the National Institutes of Health (Anderson *et al.*, 1990). The results of this trial, which are yet to be published in detail, were encouraging and have spawned the development of many new gene therapy trials.

The majority of gene therapy trials under way are for the treatment of acquired disorders such as AIDS, malignancies, and cardiovascular disease, rather than diseases arising from single gene defects (Table 5-1). The application of gene therapy to acquired disorders has proceeded

faster than applications for single-gene defects for several reasons. Principle among these reasons is that the long-term gene expression (months to years) that is likely necessary to treat genetic diseases has been difficult to achieve. The availability of a large pool of candidate patients with severe and immediately life-threatening acquired disorders (most notably cancer and AIDS) provides a clinical setting to develop new strategies for DNA delivery that may be applied later to inherited disorders. In contrast to the inherited diseases where a genetic defect has been well characterized, in most applications of gene therapy to acquired illnesses, the molecular basis of the disease is less well understood. Rather than correct a known underlying defect, the approach has been to add new molecular functions that are capable of altering the course of the disease, or to block an existing function, rather than correct an underlying deficiency.

### General Considerations in Gene Therapy

**Inherited Disorders.** The insertion of a new gene that ultimately corrects a deficiency requires that the new gene product is present in sufficient amounts to achieve a therapeutic effect. The level of protein function necessary to achieve complementation of the defect varies widely among genetic diseases. Often this can be estimated from clinical observations comparing the severity of the disease with the extent of deficiency. This is seen in the hemophilias, where the extent of bleeding complications is roughly proportional to the extent of the deficiency. Such estimates are not possible in other disorders such as cystic fibrosis, where the amount of cystic fibrosis transport regulator (CFTR) gene expression, in the airway and in other epithelial cells, necessary to achieve therapeutic benefit is not known. Here, the severity of the illness correlates with the type of genetic defect, rather than with the level of protein expression. These issues become more complex in diseases where gene expression must be carried out in a highly regulated fashion. One such example is the thalassemias, which arise from defects in the synthesis of either the  $\alpha$  or  $\beta$  chain of hemoglobin. Excessive production of either subunit chain by an unregulated therapeutic gene transfer could be as harmful as the disease itself.

**Acquired Disorders.** Mechanistically, gene therapy for acquired disorders is potentially more flexible, in terms of the inserted DNA, than gene therapy for inherited disorders. In inherited disorders, a single defective gene that causes the disorder typically is the subject of intervention. By contrast, in acquired diseases, either a defective gene

T  
T  
N  
—  
PR  
—  
Ge  
tt  
Im  
T  
Im  
Ir  
Ex  
Tre  
w  
Imu  
Gen  
Gen  
wi  
A F  
A  
Hi  
Pha  
Re  
Ger  
Ki  
Imn  
wi  
Imn  
Pat  
Clin  
Lu  
Gen  
Gen  
Cyst  
Phas  
Gr  
Cel  
Adm  
of I  
A Ph  
Vec  
Gene  
A Ph  
Dis:  
Use  
Hen  
Immu  
Gene  
Retro  
of P  
A Pre  
HIV  
\*The  
C

**Table 5-1**

**Therapeutic Gene Therapy Trials Approved by the Recombinant DNA Advisory Committee of the National Institutes of Health.\***

PROTOCOL TITLE	PRINCIPAL INVESTIGATOR	DATE OF APPROVAL
Gene Therapy of Patients with Advanced Cancer Using Tumor Infiltration Lymphocytes Transduced with the Gene Coding for Tumor Necrosis Factor.	S.A. Rosenberg	7/31/90
Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (TNF)	S.A. Rosenberg	10/7/91
Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (IL-2).	S.A. Rosenberg	10/7/91
<i>Ex vivo</i> Gene Therapy of Familial Hypercholesterolemia.	J.M. Wilson	10/8/91
Treatment of Severe Combined Immune Deficiency (SCID) Due to Adenosine Deaminase (ADA) Deficiency with Autologous Lymphocytes Transduced with the Human ADA Gene: An Experimental Study	R.M. Blaese	2/10/92
Immunotherapy of Malignancy by <i>in vivo</i> Gene Transfer into Tumors	G.J. Nabel	2/10/92
Gene Transfer for the Treatment of Cancer.	S.M. Freeman	2/10/92
Gene Therapy for the Treatment of Recurrent Glioblastoma Multiforme with <i>in vivo</i> Tumor Transduction with the Herpes Simplex-Thymidine Kinase Gene/Ganciclovir System.	K.W. Culver	3/1/92
A Phase I Study, in Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Human Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung.	R.G. Crystal	5/17/92
Phase I Study of Cytokine-Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma.	M.K. Brenner	6/1/92
Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir	E. Oldfield	6/1/92
Immunization with HLA-A2-Matched-Allogeneic-Melanoma-Cells that Secrete Interleukin-2 in Patients with Metastatic Melanoma.	B. Gansbacher	6/2/92
Immunization with Interleukin-2 Secreting Allogeneic HLA-A2 Matched Renal Cell Carcinoma Cells in Patients with Advanced Renal Cell Carcinoma.	B. Gansbacher	6/2/92
Clinical Protocol for Modification of Oncogene and Tumor Suppressor Gene Expression in Non-Small Cell Lung Cancer (NSCLC).	J.A. Roth	9/15/92
Gene Therapy of Cancer: A Pilot Study of IL-4 Gene Modified Antitumor Vaccines.	M.T. Lotze	9/15/92
Gene Therapy of Cystic Fibrosis Lung Diseases Using E1 Deleted Adenoviruses: A Phase I Trial.	J.M. Wilson	12/3/92
Cystic Fibrosis Gene Therapy Using an Adenovirus Vector: <i>In vivo</i> Safety and Efficacy in Nasal Epithelium.	M.J. Welsh	12/4/92
Phase I Study of Non-Replicating Autologous Tumor Cell Injections Using Cells Prepared With or Without Granulocyte-Macrophage Colony Stimulating Factor Gene Transduction in Patients with Metastatic Renal Cell Carcinoma.	J. Simons	3/1/93
Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts.	H.E. Heslop	3/2/93
A Phase I Study of Gene Therapy of Cystic Fibrosis Utilizing a Replication Deficient Recombinant Adenovirus Vector to Deliver the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Airways.	R.W. Wilmott	3/2/93
Gene Therapy for Cystic Fibrosis Using E1 Deleted Adenovirus: A Phase I Trial in the Nasal Cavity.	R.C. Boucher	3/2/93
A Phase I Trial of Human Gamma Interferon-Transduced Autologous Tumor Cells in Patients With Disseminated Malignant Melanoma.	H.F. Seigler	6/7/93
Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Ovarian Cancer: A Pilot Trial.	A.B. Deisseroth	6/7/93
Immunotherapy for Cancer by Direct Gene Transfer into Tumors	G.J. Nabel	6/7/93
Gene Therapy for Gaucher Disease: <i>Ex vivo</i> Gene Transfer and Autologous Transplantation of CD34+ Cells.	J.A. Barranger	6/7/93
Retroviral Mediated Transfer of the cDNA for Human Glucocerebrosidase into Hematopoietic Stem Cells of Patients with Gaucher Disease.	S. Karlsson	6/7/93
A Preliminary Study to Evaluate the Safety and Biologic Effects of Murine Retroviral Vector Encoding HIV-1 Genes [HIV-IT(V)] in Asymptomatic Subjects Infected with HIV-1.	J.E. Galpin	6/7/93

\*The protocols listed were approved through August, 1994. Detailed protocols for these clinical trials are published in the monthly journal *Human Gene Therapy*.

(Continues)

Table 5-1

**Therapeutic Gene Therapy Trials Approved by the Recombinant DNA Advisory Committee of the National Institutes of Health.\* (Continued)**

PROTOCOL TITLE	PRINCIPAL INVESTIGATOR	DATE OF APPROVAL
A Molecular Genetic Intervention for AIDS—Effects of a Transdominant Negative Form of Rev.	G.J. Nabel	6/7/93
Gene Therapy for the Treatment of Recurrent Pediatric Malignant Astrocytomas with <i>in vivo</i> Tumor Transduction with the Herpes Simplex-Thymidine Kinase Gene.	C. Raffel	6/8/93
Human MDR Gene Transfer in Patients with Advanced Cancer.	C. Hesdorffer	6/8/93
Gene Therapy for Human Brain Tumors Using Episome-Based Antisense cDNA Transcription of Insulin-Like Growth Factor I.	J. Ilan	6/8/93
Immunization of Malignant Melanoma Patients with Interleukin 2-Secreting Melanoma Cells Expressing Defined Allogeneic Histocompatibility Antigens.	T.K. Das Gupta	9/10/93
Retroviral Mediated Transfer of the Human Multi-Drug Resistance Gene (MDR-1) into Hematopoietic Stem Cells During Autologous Transplantation after Intensive Chemotherapy for Breast Cancer.	J. O'Shaughnessy	9/9/93
Gene Therapy for Recurrent Pediatric Brain Tumors.	L.E. Kun	9/9/93
A Phase I Clinical Trial to Evaluate the Safety and Effects in HIV-1 Infected Humans of Autologous Lymphocytes Transduced with a Ribozyme that Cleaves HIV-1 RNA.	F. Wong-Staal	9/10/93
Genetically Engineered Autologous Tumor Vaccines Producing Interleukin-2 for the Treatment of Metastatic Melanoma.	J.S. Economou	9/10/93
Intrathecal Gene Therapy for the Treatment of Leptomeningeal Carcinomatosis.	E.H. Oldfield	12/2/93
Injection of Colon Carcinoma Patients with Autologous Irradiated Tumor Cells and Fibroblasts Genetically Modified to Secrete Interleukin-2.	R.E. Sobol	12/2/93
Retrovirus-Mediated Transfer of the cDNA for Human Glucocerebrosidase into Peripheral Blood Repopulating Cells of Patients with Gaucher's Disease.	F. Schuening	12/2/93
An Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (V) (HIV-1 IIBenv/Retroviral Vector) in HIV-1 Infected Subjects.	R. Haubrich	12/3/93
A Phase I Trial of B7-Transfected Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell Mediated Immunity Against Tumor-Associated Antigens Presented by HLA-A1 in Patients with Stage IV Melanoma.	M. Sznol	12/3/93
Phase I Study of Immunotherapy of Advanced Colorectal Carcinoma by Direct Gene Transfer into Hepatic Metastases.	J. Rubin	12/3/93
Adoptive Immunotherapy of Melanoma with Activated Lymph Node Cells Primed <i>in vivo</i> with Autologous Tumor Cells Transduced with the IL-4 Gene.	A.E. Chang	12/3/93
Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer: A Phase I Trial of Safety and Efficacy in the Nasal Airway.	E.J. Sorscher	12/3/93
Adenovirus-Mediated Gene Transfer of CFTR to the Nasal Epithelium and Maxillary Sinus of Patients with Cystic Fibrosis.	M.J. Welsh	12/3/93
A Phase I Study of Immunization with Gamma Interferon Transduced Neuroblastoma Cells.	J. Rosenblatt	3/3/94
A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T-Lymphocytes in HIV-Infected Identical Twins.	R. Walker	3/3/94
Expression of an Exogenously Administered Human Alpha-1-Antitrypsin Gene in the Respiratory Tract of Humans.	K. Brigham	3/3/94
Phase I Study of Immunotherapy for Metastatic Renal Cell Carcinoma by Direct Gene Transfer into Metastatic Lesions.	N. Vogelzang	3/4/94
Phase I Study of Immunotherapy of Malignant Melanoma by Direct Gene Transfer.	E. Hersh	3/4/94
Phase I Trial of a Polynucleotide Augmented Anti-Tumor Immunization of Human Carcinoembryonic Antigen in Patients with Metastatic Colorectal Cancer.	D. Curiel	6/9/94
Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-arthritis Cytokine Gene to Human Joints with Rheumatoid Arthritis.	C.H. Evans	6/9/94
Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Breast Cancer: A Pilot Trial.	A. Deisseroth	6/9/94

\*The protocols listed were approved through August, 1994. Detailed protocols for these clinical trials are published in the monthly journal *Human Gene Therapy*.

Table 5-1

**Therapeutic Gene Therapy Trials Approved by the Recombinant DNA Advisory Committee of the National Institutes of Health.\* (Continued)**

PROTOCOL TITLE	PRINCIPAL INVESTIGATOR	DATE OF APPROVAL
Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients.	J.M. Liu	6/9/94
Clinical Protocol for Modification of Tumor Suppressor Gene Expression and Induction of Apoptosis in Non-Small Cell Lung Cancer (NSCLC) with an AdenovirusVector Expressing Wildtype p53 and Cisplatin.	J.A. Roth	6/10/94
Infection of Glioblastoma Patients with Tumor Cells Genetically Modified to Secrete Interleukin-2 (IL-2): A phase I Study.	R.E. Sobol	6/10/94
IL-2 Gene Therapy Using Direct Injection of Tumor with Genetically Engineered Autologous Fibroblasts.	M.T. Lotze	6/10/94
Phase I/II Study of Autologous Human GM-CSF Gene Transduced Prostate Cancer Vaccines in Patients with Metastatic Prostate Carcinoma.	J. Simons	8/3/94

\*The protocols listed were approved through August, 1994. Detailed protocols for these clinical trials are published in the monthly journal *Human Gene Therapy*.

that directly contributes to the disorder, or a gene that mediates an unrelated biochemical process, may be the basis for intervention. This diversity of approaches in treating acquired illnesses is illustrated in the gene therapy strategies that have been proposed for treating AIDS and various cancers. Treatment of HIV infection potentially could rely on the interruption of viral processes that directly contribute to the pathogenesis of AIDS. This could be achieved by several means, including inserting a gene that produces antisense mRNA, catalytic RNA (ribozymes), or a dominant negative mutant protein.

**Vaccination.** Gene transfer-mediated vaccination has become a rapidly expanding field and is applicable to the treatment of both noninfectious and infectious diseases.

**Vaccination Against Noninfectious Diseases.** Gene therapy for neoplastic diseases includes efforts to engineer an immune response to tumor cells. The idea that tumor cells can be used to elicit an antitumor immune response is founded in rare clinical observations of spontaneous tumor regression, the fact that some tumors are more common in immunocompromised hosts, and the discovery of tumor-associated antigens on many different tumor types. The general strategies proposed include transducing autologous tumor cells (or tumor infiltrating lymphocytes) to secrete a specific cytokine (e.g., tumor necrosis factor, interleukin-2, interleukin-4, interferon gamma, etc.), inducing tumor cell expression of a strong rejection antigen (e.g., allogeneic major histocompatibility or MHC molecules), and inducing tumor cell expression of lymphocyte costimulatory molecules (e.g., B7-1). Several of these approaches have reached the stage of clinical trials, but the data from these phase I studies are limited and insufficient to indicate their therapeutic effectiveness (for reviews of this topic, see Nabel *et al.*, 1994).

**Vaccination Against Infectious Diseases.** The use of gene transfer to stimulate immunity to infectious agents also is under investigation. Insertion of DNA sequences that encode key antigens from patho-

genic agents (subunit vaccines) would allow for the cellular synthesis and presentation of these antigens in a manner that physiologically mimics their presentation during infections, without the risks of actual exposure to the pathogenic organism. This could have significant implications in the development of an HIV vaccine where the safety implications of a live, attenuated HIV vaccine are awesome.

### Obstacles to Gene Therapy

The therapeutic applications of gene transfer technology increase with each discovery of a new cellular process. At present, our ability to develop clinically efficacious therapies from scientifically sound principles is limited by several problems that, to some extent, plague all gene therapy strategies. For the foreseeable future, gene therapy is limited to somatic cells (nongerm-line cells). How these cells in a given tissue are targeted by the DNA delivery method has been an area of intense interest. Once the gene has been successfully transferred, the duration of transgene expression becomes important. Finally, the DNA vector itself must be analyzed for its potential to cause unwanted side effects (Jolly, 1994).

**DNA Delivery and Pharmacokinetics.** The delivery of exogenous DNA and its processing by target cells require the introduction of new pharmacokinetic paradigms beyond those that describe the conventional medicines in use today (see Chapter 1). With *in vivo* gene transfer, one must account for the fate of the DNA vector itself (volume of distribution, rate of clearance into tissues, etc.), as well as for the consequences of altered gene expression and protein function. A multicompartmental model to describe these events in a quantitative fashion has been developed

(Ledley and Ledley, 1994). Processes that must be considered include the distribution of the DNA vector following *in vivo* administration; the fraction of vector taken up by the target cell population; the trafficking of the genetic material within cellular organelles; the rate of degradation of the DNA; the level of mRNA produced; the stability of the mRNA produced; the amount and stability of the protein produced; and the protein's compartmentalization within the cell, or its secretory fate, once produced. It is conceivable, although yet to be realized, that each of these events may be incorporated into the design of the gene transfer system in a rational way so as to tailor the gene transfer to the specific requirements of the disease being treated.

**Duration of Expression of Transferred Gene.** The length of time over which the transferred gene will function is of tremendous importance. In the treatment of inherited diseases, it would be desirable to have stable gene expression over many years. In contrast, in the treatment of malignancy, it is possible that the long-term production of the therapeutic protein could have deleterious consequences. Durable gene expression has yet to be conclusively demonstrated by any of the human trials to date, but this relates as much to the short term of follow-up as to experimental design. Vectors that integrate the transferred DNA into the chromosomes of the recipient cell have the greatest potential for long-term expression. Retroviral vectors and adeno-associated viral vectors have integrating functions. The persistence of the transgene DNA in the DNA of the recipient cell does not, however, guarantee long-term gene expression in that cell. The production of the intended mRNA and protein may decline due to inactivation of the transgene promoter even though the DNA persists. In some circumstances, loss of transgene expression may occur due to loss of the transduced cell by host immune processes (see Jolly, 1994, for detailed discussion of this issue).

**Adverse Consequences of Heterologous Gene Expression.** Along with factors that limit gene transfer and expression, there is a growing list of adverse consequences that may arise as a result of successful gene transfer. As with any new drug, it will be impossible to predict these events in advance of more clinical experience. Nonetheless, some specific events can be anticipated independent of the transgene employed. Because, in most circumstances, gene transfer will result in the synthesis of a new protein, the possibility of an immune response must be considered. A severe immune response could inactivate a secreted product (as is seen in hemophilia patients receiving factor VIII replacement therapy) or lead to an "autoimmu-

ne" response to transduced tissues. In some circumstances, the DNA vector itself may be immunogenic, as has been demonstrated for adenovirus vectors. An immune response to the vector may preclude its readministration or limit the duration of its effectiveness.

Pathological events may arise from viral vector replication. Significant efforts have been directed toward the design of viral vectors that are unable to replicate (replication-incompetent) in the target cell. This has been achieved by the deletion of specific genes from the viral genome that are necessary for viral replication (Miller *et al.*, 1993; *see also* legends to Figures 5-1 and 5-2). In order to produce the virus, it must then be grown *in vitro* in a cell specifically designed to provide those functions removed from the virus. By these means, replication-defective retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses have been produced. This approach does not completely eliminate replicative potential in all circumstances. The virus may overcome the deletion of replication machinery by the use of unidentified host cell factors or by recombination in the patient with wild-type viruses. Fortunately, in the limited patient experience to date, these events have not been reported.

### Ethical Issues

As with any new technology, much attention has been directed toward ethical issues of gene therapy. Many of these issues are common to all new and expensive forms of medical treatment, such as who will have access to the therapy, and who will pay for it. The perception that this technology could be used for germ-line genetic engineering has spawned much discussion as well (Neel, 1993). Also of concern is the possibility that gene transfer techniques would be used for "frivolous" purposes such as cosmetic alterations. While these issues likely will be topics of continued debate, they, at present, deal with very unlikely events. For example, gene transfer into germ-line tissues to prevent future generations of affected children would require "prophylactic" treatment of prospective parents. Since the risk of having an affected child in the vast majority of cases is either one in two (autosomal dominant disease), or one in four (autosomal recessive disease), and the treatment will be neither without risk nor 100% effective, it is unlikely that any reasonable parent would submit to such a procedure. Even if there were successful introduction of a new gene during the process of *in vitro* fertilization, it is unlikely that the corrected phenotype would persist for more than one generation. The new gene would have to be inserted into the same chromosome (23 to 1 odds against this), and in close proximity to the de-

fec  
ger  
atic  
we  
tor:  
ger  
the

The  
acc  
ava  
cou  
mit  
exp  
a I  
ava  
wit  
get  
tor  
tria  
tier  
wil  
rat

Vi

Th  
a 1  
tra  
exc  
ple  
sul  
lea  
ral  
ter  
tio  
tra  
rer  
thi  
vir  
ica  
ap

Re  
cli  
pre

fective gene (100 to 1 odds against this), so that the new gene would be tightly linked to the defective gene. Alteration of normal characteristics is even more farfetched, as we have only a primitive understanding of the many factors that control physical appearance, personality, intelligence, and physical ability, and the genetic contribution to these characteristics.

### TECHNOLOGIES FOR *in vivo* GENE TRANSFER

The ideal DNA delivery system would be one that could accommodate a broad size range of inserted DNA, was available in a concentrated form, was easily produced, could be targeted to specific types of cells, would not permit replication of the DNA, could provide long-term gene expression, and was nontoxic and nonimmunogenic. Such a DNA delivery system does not exist, and none of the available technologies for *in vivo* gene transfer is perfect with respect to any one of these points. As of 1995, three gene transfer systems (retroviral vectors, adenoviral vectors, and liposomes) had been used in human gene therapy trials, with a total clinical experience of a few hundred patients worldwide. Consequently, the following discussion will highlight conceptual strategies and issues to be refined, rather than clinical experience.

#### Viral Vectors

The natural life cycle of mammalian viruses has made them a logical starting point for the design of therapeutic gene transfer vehicles, because viruses all transfer and express exogenous genetic material during infection. In the simplest analysis, a virus consists of genetic material encapsulated in a particle that can be taken up by the target cell, leading to the expression of virally encoded genes. For viral vectors to be useful, several viral functions must be altered. At a minimum, the virus must be rendered replication-incompetent to prevent uncontrolled spread of the transgene and must have some element of its own genome removed to allow for insertion of the transgene. Beyond this, additional modifications are dependent on the specific virus. Viral vectors have been used extensively in preclinical research and are the basis for the majority of gene therapy clinical trials now underway.


**Retroviruses.** Retroviral vectors have had the greatest clinical use so far and offer the potential for long-term expression from a stably integrated transgene. They lack ir-

relevant and potentially immunogenic proteins, and there is no preexisting host immunity to the vector. Their application, however, is limited to dividing cells. Large-scale production is technically possible, although purification and concentration potentially are problematic due to the instability of the virus. Several safety issues have been raised but have not as yet been supported by clinical experience.

Retroviruses were first described for gene transfer applications in 1981 and first utilized in clinical trials in 1989 (Rosenberg *et al.*, 1990). Retroviruses are composed of an RNA genome that is packaged in an envelope derived from host cell membrane and viral proteins. For the retrovirus to effect gene expression, it must first reverse transcribe its positive-strand RNA genome into double-stranded DNA, which is then integrated into the host cell DNA. This process is mediated by reverse transcriptase and integrase proteins contained in the retrovirus particle. The integrated provirus is able to use host cell machinery to carry out transcription of viral mRNAs and their subsequent processing and translation into viral proteins. The virus completes its life cycle by synthesizing new positive-strand RNA genomes from the integrated provirus. An encapsidation signal ( $\psi$ ) within the RNA mediates the organization of the viral genomic RNA and proteins into particles that bud from the cell surface.

**Design of the Retroviral Vector.** The genomic organization of retroviruses is simple, and this property facilitates its manipulation into vectors for use in gene therapy. The murine leukemia virus and its congeners are the most widely used retroviral vectors (Miller *et al.*, 1993). Retroviral vectors are constructed from the proviral form of the virus. The *gag*, *pol*, and *env* genes are removed to make room for the gene(s) of therapeutic interest and to eliminate the replicative functions of the virus (see Figure 5-1 for a strategic overview). Up to 8 kilobases of heterologous DNA can be incorporated into the retroviral vector. Because all virally encoded mRNAs are eliminated from the recombinant retrovirus, no viral proteins are produced by retroviral vectors. This removes any potential viral-encoded antigens that might lead to an immune response to the transduced cells. Along with the gene of therapeutic interest, genes encoding antibiotic resistance often are included in the recombinant retrovirus as a means of selecting the virus-harboring cultured cells *ex vivo*. The bacterial gene for aminoglycoside-3'-phosphotransferase, which confers resistance to kanamycin, neomycin, and geneticin, and the gene for hygromycin B phosphotransferase, which confers resistance to hygromycin, are two such examples of antibiotic resistance genes introduced into retroviral vectors for gene therapy. The presence of an antibiotic resistance gene facilitates isolation of the recombinant retrovirus and subsequent determination of virus titer. Sequences containing promoter and enhancer functions also may be included with the transgene to facilitate its efficient expression and, in some circumstances, to provide for tissue-specific expression after administration *in vivo*. Alternatively, the promoter and enhancer functions contained in the long terminal repeat of the virus may be used for this purpose.

**Packaging Cell Lines.** After deletion of the genes encoding viral structural proteins and proteins that mediate viral replication, these viruses can be produced only in specially engineered viral packaging cell lines that are capable of providing these proteins (see Figure 5-1). The packaging cell line is optimally constructed by stably inserting the deleted viral genes (*gag*, *pol*, and *env*) into the cell in such a manner that these genes will reside on different chromosomes within the packaging cell. This strategy ensures that recom-



**Figure 5–1.** Retrovirus-mediated gene transfer.

**A. Overall strategy of retroviral production.** Replication defective retrovirus vectors are produced from a helper cell that is engineered to provide viral functions (DNA) which have been removed from the virus. The *gag* (G), *pol* (P), and *env* (E) DNA sequences are cloned into DNA plasmids which are then transfected into the helper cell to produce the *packaging cell*. Packaging cells are able to produce the *gag*, *pol*, and envelope proteins required for retroviral replication. A plasmid containing recombinant proviral DNA, but lacking *gag*, *pol*, and *env* genes, is transfected into the packaging cell line to create the *producer cell* which contains all of the molecular machinery necessary to reproduce the recombinant retrovirus that is secreted into the tissue culture medium. Only the recombinant proviral sequence is packaged into the retrovirus. Because the recombinant retrovirus does not contain the *gag*, *pol*, and *env* genes, cells that this replication-defective recombinant retrovirus infects cannot produce additional virions.

#### **B. Expression of gene of interest in target cell following retrovirus-mediated RNA delivery.**

bination of these genes is highly unlikely. In the absence of such a recombination, it is impossible to produce an intact viral genomic RNA that could be packaged into a replication-competent virus. The packaging cell line is used to construct a retroviral producer cell line that will generate replication-defective retrovirus containing the gene(s) of interest. This is done by inserting the recombinant proviral DNA into the packaging cell line. The recombinant proviral DNA is in the form of plasmid DNA containing the long terminal repeat sequences flanking a small portion of the *gag* gene that contains the encapsidation sequence and the genes of interest. This is transfected into the packaging cell line using any number of standard techniques for DNA transfer and uptake (electroporation, calcium precipitation, *etc.*). Several versions of this basic design have been employed to decrease the likelihood of recombinant events that could lead to the production of replication-competent virus (Jolly, 1994). Additional modifications have been employed to alter the host cell range of the virus. This is determined to a large extent by the envelope gene (*env*). The Moloney murine leukemia virus envelope is ecotropic, which means that infection is restricted to the cells of a particular species, in this case mouse. An envelope affording a broader infection range is available by using the *env* gene from the 4070A strain of murine leukemia virus. This envelope gene has amphotropic specificity and can promote the infection of human, murine, and other mammalian cells. *Env* genes with specificities that extend the host range to nonmammalian cells also are available. Efforts to design new ligands into the envelope protein have met with limited success, as the virus produced often is of low titer. Nonetheless, the ability to specifically target the virus by redesign of its molecular structure is an important goal and undoubtedly will receive more attention in the future.

**Clinical Administration of Retroviruses.** The clinical administration of retroviruses has been accomplished by the *ex vivo* transduction of patients' cells, by the direct injection of virus into tissue, and by the administration of the retroviral producer cells.

**Ex Vivo Gene Transfer.** The *ex vivo* approach has been most widely employed in human clinical trials. Although cumbersome in that it requires the isolation and maintenance in tissue culture of the patient's cells, it has the advantage that the extent of gene transfer can be quantified readily and a specific population of cells can be targeted. In addition, a high ratio of viral particles to target cells can be achieved and thus improve the transduction efficiency. This approach was used to modify lymphocytes (Anderson *et al.*, 1990; Rosenberg *et al.*, 1990; Culver *et al.*, 1991) and hematopoietic cells (Nienhuis *et al.*, 1991), in the treatment of adenosine deaminase deficiency (Anderson *et al.*, 1990), in the treatment of hyperlipidemia (Grossman *et al.*, 1994) (see Figure 5-4, below), and to express immune modulatory agents in tumor cells (Lotze *et al.*, 1992; Lotze, 1993; Lotze *et al.*, 1994). Clearly, not all potential disease applications are amenable to *ex vivo* gene transfer, as the removal and culture of patient cells may not be technically possible. In such circumstances, direct introduction of the virus *in vivo* is necessary.

**In Vivo Gene Transfer.** Retroviruses are being tested as potential agents to treat brain tumors which, in many circumstances, are relatively inaccessible. Here, the inherent ability of a retrovirus to transduce only dividing cells (tumor cells) and leave nondividing cells (normal brain parenchyma) untouched may be particularly advantageous. Although the direct stereotactic injection of recombinant retrovirus into the target tissue is possible, the efficiency of gene transfer generally is very low.

Several factors contribute to the inefficiency of retroviral gene transfer *in vivo*. Retrovirus preparations are relatively dilute compared with other vectors, typically with  $10^6$  to  $10^8$  plaque forming units per milliliter. Furthermore, the virus can transduce only dividing cells, and within the target tissue only a small fraction of cells may be dividing in the time interval between virus injection and virus clearance. Thus, even with a large excess of virus, only a fraction of the cells are effectively transduced. To overcome these difficulties, Oldfield and colleagues (1993) proposed the administration of a retrovirus producer cell line directly into patients' brain tumors using stereotactic injection. Their hypothesis was that the murine producer cell would survive within the brain tumor for a period of days, and that over this time period would secrete retrovirus capable of transducing the surrounding brain tumor. Studies are in progress in a limited number of patients using virus carrying the herpes virus thymidine kinase gene. This gene renders the cells susceptible to killing by the systemically administered antibiotic ganciclovir, which is metabolized to a cytotoxic metabolite by thymidine kinase. Several important issues will need to be addressed before this approach gains widespread acceptance. The ability of the virus to diffuse from the producer cell to nonneighboring tumor cells is not yet well quantified. If the area of transduced tumor cells is small, tumor cells lying in microscopic cords of tumor infiltrating normal brain might go untreated. Also unknown is whether an immune response to the xenogeneic producer cell line precludes subsequent retreatment of residual tumor. This will be very important given that, over the time of virus secretion, all tumor cells may not be actively dividing, and therefore some cells might go unscathed. Serial treatments, as in conventional chemotherapy, might be required to achieve complete tumor eradication. The results of clinical trials now under way and subsequent studies may answer these questions.

**Safety of Retroviral Vector Strategies.** The use of retroviral vectors has raised several important safety issues. One concern is that because the virus integrates into the target cell chromosomes (an attractive feature for long-term expression) and because integration occurs in a nearly random fashion, integration could be mutagenic. For example, undesired mutations might occur if insertion of the retroviral DNA altered the function of a cell growth regulating gene. Although replication-competent retroviruses have tumorigenic potential, this has not been observed with the replication-defective vectors that are in use as gene transfer agents. Additionally, this has not been observed in any patients who have received retroviral gene therapy. However, the number of patients studied to date is too few and their follow-up too short for current clinical experience to be extrapolated to long-term safety.

Demonstrating that retroviral agents are free of replication-competent virus is of paramount importance. Replication-competent virus could arise by several means. As noted earlier, recombination of the retroviral genetic elements inserted into the packaging cell line is exceedingly unlikely. Recombination with other retroviral genomes is, however, theoretically possible. There exist homologous endogenous retroviral sequences within the mouse cell lines used to create packaging cell lines. The use of dog- or human-derived packaging cell lines that are free of such sequences has been proposed (Jolly, 1994). Recombination with retroviral sequences in the target cell is theoretically possible. Wild-type murine retroviruses, from which genetic vectors are derived, do not infect human cells. Therefore, it is unlikely that a wild-type virus could infect the same target cell and lead to rescue of the defective retroviral vector. However, there do exist endogenous retroviruses in all human tissue (HERV-K retroviruses)

that have low-level homology to the retroviral vectors. It is very unlikely that this type of recombination would occur with sufficient frequency to lead to clinically significant adverse outcomes. In the final analysis, the safety of these and other vectors must be determined by direct clinical experience and their safety weighed against their therapeutic benefits.

**Adenoviruses.** Over 40 serotypes of human adenoviruses are known, and many animal adenoviruses have been characterized to varying degrees. The clinical spectrum of human adenoviral infections is well described (see Horwitz, 1990). Infections involving the respiratory tract are common and typically self-limited in normal hosts. Gastrointestinal, urinary, hepatic, and CNS infections occur sporadically. Most, if not all, adults have prior exposure to adenovirus and are seropositive for antiadenovirus antibodies when tested by sensitive methods. In the United States, military recruits specifically are vaccinated with a polyclonal adenoviral vaccine to prevent outbreaks of respiratory infections (Rubin and Rorke, 1994). In contrast to the retroviruses, these larger, nonenveloped viruses possess a double-stranded DNA genome, and replicate independent of host cell division.

Adenoviral vectors possess several attractive features that have encouraged their development for clinical use. They are capable of transducing a broad spectrum of human tissues, including respiratory epithelium, vascular endothelium, cardiac and skeletal muscle, peripheral and central nervous tissue, hepatocytes, the exocrine pancreas, and many tumor types. Exceptionally high levels of gene transfer and transgene expression can be obtained in dividing and nondividing cells. Several routes of administration can be used including intravenous, intrabiliary, intraperitoneal, intravesicular, intracranial and intrathecal injection, and direct injection of the target organ parenchyma. So far it has not been possible to modify the adenovirus to achieve a tissue-specific virus. The multiple routes of administration may overcome this deficiency by providing flexibility in targeting based on anatomical boundaries.

Clinical trials using adenovirus have been limited to date to the ongoing protocols for cystic fibrosis, where the recombinant adenovirus is delivered by aerosolization into the respiratory tract. Studies using direct administration of adenoviral vectors into the liver to treat inherited genetic deficiencies and into a variety of tumors likely will begin in the near future (see Ohno *et al.*, 1994, and Kozarsky *et al.*, 1994, as two examples of adenoviral gene therapy strategies).

The genomic structure of adenoviruses is more complex than that of retroviruses. The adenoviral genome encodes approximately 15 proteins. Infection takes place when the fiber protein, which extends from the icosahedral capsid, binds a cell surface receptor. Subsequently, peptide sequences in the penton base portion of the capsid engage in-

tegrin receptor domains ( $\alpha_3\beta_3$ , or  $\alpha_3\beta_5$ ) on the cell surface. This leads to virus internalization via endosomal pathways where the viral particle begins to disassemble. The virus escapes the endosome prior to its fusion with lysosomal compartments and thus avoids digestion. The viral DNA is able to enter the target cell nucleus and begin transcription of viral mRNA without concomitant cell division. Although integration of viral DNA into the host cell genomic DNA can occur at high levels of infection in dividing cells, this is a relatively infrequent event and does not contribute significantly to the utility of these viruses as vectors. Viral gene expression and replication occur in an ordered fashion and are driven in large measure by the E1A and E1B genes in the 5' portion of the adenoviral genome. The E1A and E1B genes provide transactivation functions for transcription of several of the downstream viral genes (see Horwitz, 1990).

Since the E1 genes are involved intimately in adenovirus replication, their removal renders the virus replication-incompetent or, at the very least, severely crippled with respect to replication. Due to the complexity of the virus, it has been more difficult to remove all adenoviral genes as is done with retroviral vectors. The expression of adenoviral proteins, with the currently employed adenoviral vectors, leads to both a cellular and a humoral immune response to recombinant adenoviral vectors. In some instances, this may limit the utility of this vector both in terms of host immune response to adenovirally transduced cells and with respect to readministration of the vector.

**Design of Adenoviral Vectors for Gene Therapy.** Although several adenoviral serotypes are known, serotypes 2 and 5 have been most extensively used for vector construction. Adenoviral vectors can be constructed using one of several general approaches. A schematic diagram outlining the basic elements of an adenoviral vector design for gene therapy is shown in Figure 5-2. Bett and colleagues (1994) have developed an adenoviral type 5 vector system based on bacterial plasmids containing the adenovirus genome with deletions of the E1 and E3 adenoviral genes. Deletion of E1 renders the virus replication-defective. In addition, all or part of the E3 region, which is not essential for virus function, is deleted in order to accommodate the DNA inserted into the adenovirus genome. Genes of interest can be cloned into the deletion regions, and the plasmid vector can then be grown in bacterial culture. The purified plasmid DNA subsequently is transfected into the 293 line of human embryonic kidney cells. The 293 cell line has been engineered to express E1 proteins and can thus transcomplement the E1-deficient viral genome. The virus can be isolated from 293 cell media and purified by limiting dilution plaque assays (Graham and Preveck, 1991). An alternative approach is to prepare a plasmid containing the gene of interest, flanked by adenovirus DNA sequences. Transfection of this plasmid into 293 cells along with genomic adenovirus DNA with selected deletions (e.g., E3) leads to formation of adenoviral particles with the transgene replacing E1 genes by homologous recombination. It is this strategy that is given in detail in Figure 5-2. Either direct cloning or homologous recombination can be used to produce E1-deleted, replication-defective adenovirus.

Large amounts of the engineered adenoviral vector system can be produced by growing the recombinant virus in 293 cell cultures. The virus is isolated by lysing the infected 293 cells and purifying the crude lysate by cesium chloride density centrifugation, a procedure that not only separates the virus from other tissue culture-derived substances, but also concentrates the virus to very high titers (over  $10^{13}$  particles per ml). The purified virus is remarkably stable in a variety of aqueous buffers, and can be frozen for a prolonged period of time without loss of activity.

Figures  
A. Co-  
trans-  
here i  
the ac-  
to all  
DNA i  
fected  
to pre-  
B. A  
recor  
esca  
unpa  
ing tl




Figure 5-2. Adenovirus-mediated gene transfer

**A. Construction of recombinant adenovirus for engineering cells.** Strategy for preparing recombinant adenovirus by homologous recombination. Recombinant adenovirus encoding a gene of interest can be produced by cloning the gene of interest (shown in blue) into a plasmid. This transgene is flanked by a promoter sequence (e.g., CMV promoter) and by regions of the adenovirus genome (shown in gray). The example here is based on adenovirus 5. The adenovirus 5 DNA is divided into 100 map units (m.u.; 360 base pairs per map unit). Deletions are made in the adenovirus DNA to remove E1 (1 to 9.2 m.u.) and E3 (78.4 to 84.3 m.u.) regions to eliminate the possibility of autonomous replication and to allow room for insertion of the transgene. Homologous recombination takes place between the plasmid DNA and the adenovirus genomic DNA to yield the recombinant virus. Since the transgene sequence replaces the E1 genes of the adenovirus, the adenovirus is unable to replicate in cells other than those engineered to express E1 gene products, such as the human embryonic kidney 293 cells shown here.

After linearization of the plasmid by digestion with an endonuclease (e.g., Nhe I in this example), the transgene-expressing plasmid is cotransfected with adenovirus genomic DNA from which the 5' end has been removed (e.g., digestion with the Cla I endonuclease at Ad 2.5 m.u.), also to prevent autonomous adenovirus replication, until homologous recombination takes place, which in this example occurs within the 293 cells.

**B. Adenovirus-mediated infection of target cells.** Expression of gene of interest in target cell following adenovirus-mediated DNA delivery. A recombinant adenovirus binds to specific receptors on the surface of a target cell and enters the cell by endocytosis. Viral proteins promote the escape of the adenovirus from the endosome prior to endosome fusion with and destruction by lysosomes. The adenovirus DNA becomes unpackaged from the viral proteins and travels to the nucleus where it begins to synthesize new mRNA. The adenovirus encoded DNA, including the transgene, is not integrated into the genome of the host cell. (Modified from Greber et al., 1993, with permission.)

**Duration of Transgene Expression.** Adenoviral vectors currently are limited by their relatively short duration of transgene expression. Several factors contribute to this, including clearance of transduced cells by cytotoxic T cells and other inflammatory cells (Yang *et al.*, 1994) and dilutional loss of episomal DNA during target cell division. The former likely will be solved by the design of adenoviral vectors that are less immunogenic. Vectors with temperature-sensitive mutations in the E2 region clearly are less immunogenic and offer significantly longer gene expression (Engelhardt *et al.*, 1994). Deleting the E4 gene from adenoviral vectors also may diminish the immune response to transduced cells (Armentano *et al.*, 1994). Subsequent generations of adenoviral vectors with additional modifications of the adenoviral genome or the use of nonhuman adenoviruses may advance the use of adenoviral vectors. The episomal nature of the adenovirus genome ultimately limits the duration of gene expression in tissues with active cell division such as bone marrow and epithelial surfaces. Since each round of target cell division after gene transfer is not accompanied by replication of the transgene, daughter cells will have progressively fewer and eventually no copies of the transgene. Integration of the adenoviral vector does occur, but not at a high enough frequency to be useful.

**Safety of Adenoviral Vector Strategies.** The safety of adenoviral vectors likely will be borne out by current clinical trials. The principal side effects are from the host immune response to the adenoviral proteins, a limitation that may be eliminated by future generations of vectors. There is some concern, however, that vector replication can take place despite removal of important regulatory genes. Since wild-type adenoviral infections are common, there exists the possibility that wild-type viruses may recombine with replication-defective vectors to produce replication-competent, recombinant virus. Although not observed in the present cystic fibrosis clinical trials, this remains a concern. Additionally, there is a growing body of evidence that some cell types may contain proteins with functions homologous to E1a and thus be able to provide a permissive environment for recombinant viral replication. With the present adenoviral vectors, this is not likely to evolve into a serious infection, given the preexisting host immunity to adenoviral infection. However, if future adenoviral vectors are able to evade this protective mechanism, then recombinant viral replication may become a greater concern.

**Adeno-Associated Virus.** Adeno-associated virus (AAV) appears to have many of the desirable features of retroviruses and adenovirus without some of their potential drawbacks for application to gene therapy (Kotin, 1994). These single-stranded DNA, nonautonomous parvoviruses are able to integrate efficiently into the genome of nondividing cells of a very broad host range. Integration of the wild-type virus is specific for chromosome 19 (19q13.3-qter), or at least shows preferential integration at this site. Although ubiquitous in nature, AAV has not been shown to be associated with any known human disease and does not elicit an immune response in an infected human host. AAV is a nonenveloped virus that is stable to a variety of chemical and physical manipulations and thus can be purified, concentrated, and stored for prolonged periods.

At present, the use of AAV as a vector for gene therapy is limited by difficulties in producing the virus in large quantities and, more importantly, by a lack of understand-

ing of the biology of the recombinant virus. For instance, it remains to be determined whether or not these vectors have the ability to infect and integrate into nondividing cells, an important feature of the wild-type virus that has promoted its use. There is little experience in human beings with these new vectors. The Recombinant DNA Advisory Committee of the National Institutes of Health has approved the first human trial of AAV in patients with cystic fibrosis. This trial may provide information about the duration of gene expression following AAV-mediated gene transfer into terminally differentiated airway epithelial cells.

AAV has two distinct phases to its life cycle. In the absence of helper virus (adenovirus), the wild-type virus will infect a host cell, integrate into the host cell genome, and remain latent for a long time. In the presence of adenovirus, the lytic phase of the virus is induced, which is dependent on the expression of early adenoviral genes, and leads to active virus replication. Structurally, the AAV genome is composed of two open reading frames (called *rep* and *cap*) flanked by inverted terminal repeat (ITRs) sequences. The *rep* region encodes four proteins which mediate AAV replication, viral DNA transcription, and endonuclease functions used in host genome integration. The *rep* genes are the only AAV sequences required for viral replication. The *cap* sequence encodes structural proteins that form the viral capsid. The ITRs contain the viral origins of replication, provide encapsidation signals, and participate in viral DNA integration. The function of many of these proteins and the overall biology of the virus have been studied largely in wild-type viruses (see Kotin, 1994). Recombinant, replication-defective viruses that have been developed for gene therapy lack *rep* and *cap* sequences. The recombinant viruses are less well studied, and it is not known whether these viruses retain all of the features of the wild-type virus (*i.e.*, site-specific integration in a nondividing cell).

Production of AAV in large quantities is considerably more difficult than production of retroviruses or adenoviruses. Replication-defective AAV can be produced by cotransfected the separated elements necessary for AAV replication into a permissive cell line (typically 293 cells). In a commonly used method, plasmid DNA containing *rep* and *cap*, under the control of AAV promoters but lacking ITRs, is transfected into 293 cells. DNA containing the gene to be "packaged" (promoter, enhancer, transgene, polyadenylation signal) flanked by ITRs is cotransfected at the same time. Infection with adenovirus provides helper functions that induce the synthesis of *rep* proteins, which in turn transactivate the synthesis of capsid proteins. The transgene flanked by ITRs is then packaged into viral particles that can be isolated and purified by cesium chloride density centrifugation. This approach requires that the plasmid expressing the ITR (ITR<sup>+</sup>; here, the transgene-encoding plasmid) have little sequence homology with ITR<sup>-</sup> plasmids (*cap* and *rep*) to reduce the likelihood of recombination events that could lead to the production of wild-type virus. Improved systems for recombinant AAV preparation are being developed including the use of producer cell lines that provide *rep* and *cap* functions. Such an approach not only would simplify the transfection scheme, but also would provide *rep* and *cap* proteins in larger quantities and thus lead to higher yields of recombinant virus.

**Vaccinia Vectors (Pox Viruses).** The extensive clinical experience with vaccinia vaccines and their ease of ma-

nipulation have led to efforts to develop gene therapy vectors from pox viruses (Moss and Flexner, 1987; Moss, 1990). Vaccinia are large, enveloped DNA viruses that replicate in the cytoplasm of infected cells. Like adenovirus, they can infect nondividing as well as dividing cells from many different tissues, and provide short-term gene expression from a nonintegrated viral genome. Recombinant virus can be produced by inserting the transgene into a vaccinia-derived plasmid and transfecting this DNA into vaccinia-infected cells. Homologous recombination leads to the generation of the recombined virus that can be plaque purified. High yields of virus are achieved easily and can be stored for long periods of time. The vaccinia viruses can accommodate much larger DNA inserts than can retrovirus, adenovirus, or AAV vectors. Additionally, since the wild-type virus no longer exists in the wild, recombination to produce new strains of virus is unlikely. A significant drawback to the use of this vector system is that it elicits a host immune response to the 150 to 200 virally encoded proteins. This is likely to make repeated administration problematic. Replication of the vector also is a concern, as it can result in significant morbidity in immunodeficient hosts. This might be overcome with newer generations of engineered vaccinia virus. At present, this vector system has not been adopted for clinical trials of human gene therapy, although it may be useful as a vaccine vector.

**Herpes Simplex Virus-1 Vectors.** The herpes simplex virus is a large (152 kb), double-stranded DNA virus that replicates in the nucleus of infected cells. It has a broad host cell range, and can infect dividing and nondividing cells as well as persist in a nonintegrated state. Large sequences of foreign DNA can be inserted into the viral genome by homologous recombination, and the replication-defective, recombinant virus can be plaque purified on transcomplementing cells (IE<sup>+</sup>). These advantages for gene therapy strategies are countered by the difficulty in rendering viral preparations totally free of replication-competent virus and the elicitation of a potent immune response to virus-encoded proteins that are directly toxic to the cell. Despite these apparent drawbacks, advantages such as their ability to accommodate large DNA inserts (20 to 30 kb), the availability of high titer stocks, and their neurotropism have stimulated interest in developing useful herpes virus vectors (see Kennedy and Steiner, 1993).

Deletion of the viral thymidine kinase gene renders the herpes virus replication-defective in cells with low levels of endogenous thymidine kinase (*i.e.*, terminally differentiated, nondividing cells). In contrast, cells undergoing active cell division (*e.g.*, tumor cells) possess sufficient thymidine kinase activity to allow the thymidine

kinase-negative herpes virus to replicate. This type of vector may be useful for treating intracranial tumors, as the tumor cells, but not the neurons, will selectively undergo gene transfer. Since vector replication occurs, systemic dissemination potentially can occur with this viral vector. This is much less likely in immunocompetent hosts because the host cellular immune response likely will control the spread of the virus. The use of herpes virus vectors in immunocompromised hosts, which may include some cancer patients, is potentially problematic (see Valyi-Nagy *et al.*, 1994).

**Other Viral Vectors.** The need for tissue-selective gene transfer has led to the consideration of a variety of other viruses, including HIV, the minute virus of mice, hepatitis B virus, and influenza virus, as possible vectors for gene transfer. These and other viruses may find applications based on aspects of their life cycle that result in tissue-selective gene expression or other unique features that lend themselves to specific diseases (see Jolly, 1994).

**Comparison of Properties of Viral Vectors for Gene Therapy.** Boviatosis and colleagues (1994) recently compared the usefulness of recombinant retrovirus, adenovirus, and herpes virus vectors in a rat brain tumor model using the gene coding for bacterial  $\beta$ -galactosidase as an indicator of gene transfer. Although their experiments did not definitely establish which vector is more efficient at gene transfer, useful distinguishing features of each vector were nonetheless noted. Following intralesional administration, the retrovirus and herpes virus vectors selectively effected gene transfer into tumor cells over neurons and other endogenous brain cells. In contrast, the adenoviral vector transduced brain tumor cells as well as neighboring normal brain parenchyma. In the case of the retroviral vector, selectivity for the tumor cell results from the virus's requirement for cell division as a prerequisite for transgene integration and expression. In the case of the herpes virus vector, the selectivity occurs as a result of differential expression of endogenous thymidine kinase in the tumor cells (very high) versus nonneoplastic cells (very low). The adenovirus showed little cell selectivity, and any preference for tumor cell expression probably was a result of the site of injection (within the tumor). Another noteworthy observation was the degree of inflammation and necrosis that occurred following gene transfer. The retroviral vector induced no significant inflammatory response, and that induced by the adenoviral vector was minimal. However, prominent inflammatory infiltrates were noted in the brain tissues following herpes virus-mediated gene transfer. Although this study suggests a useful role for the herpes virus vector in treating tumors, the clinical application of such a vector likely will be difficult. Additional measures to control replication of this human pathogen-derived vector will have to be instituted, and the consequences of a potentially

## SECTION I GENERAL PRINCIPLES

severe inflammatory response will need to be addressed. Furthermore, as Boviatsis and colleagues (1994) point out, the latency of this type of vector is unknown, and it is therefore possible that reactivation by recombination with wild-type virus (thymidine kinase positive) could occur.

### Nonviral DNA Delivery Strategies

Because of the potential limitations of viral vectors, investigators have examined the use of nonviral agents to mediate cellular uptake of exogenous DNA. These DNA delivery systems, which include uncomplexed plasmid DNA, DNA-liposome complexes, DNA-protein complexes, and DNA-coated gold particles, are constructed from known components. Therefore, their composition, unlike complex virions, is well-defined. In addition, their formulation technically is much easier than that of viruses and, in many cases, these DNA delivery systems can be produced without the need for cell culture.

**Purified Uncomplexed Plasmid DNA.** Surprisingly, purified DNA (or mRNA) can be injected directly into tissues and results in transient gene expression. This has been best illustrated in muscle tissue, where direct injection of uncomplexed DNA is most effective. Wolff *et al.* (1990) demonstrated that purified plasmid DNA or mRNA encoding a reporter gene could mediate transgene expression following direct injection into the quadriceps muscle of a mouse. DNA injection resulted in longer gene expression (substantial gene product was seen after 60 days) than did mRNA injection (expression declined after 18 hours). The DNA likely persists as unintegrated plasmid DNA rather than in an integrated form. A direct comparison of adenoviral and retroviral vectors with injected plasmid DNA in murine muscle gene transfer revealed that all three systems were more efficient at gene transfer in regenerating muscle (cardiotoxin-induced) than in mature normal mouse muscle. In regenerating muscle, these DNA transfer systems were equally efficient, as assessed by the number of muscle fibers expressing the reporter gene. Surprisingly, in mature fibers, gene transfer by direct injection of plasmid DNA was superior to that with either of the viral vectors (Davis *et al.*, 1993). In addition, no inflammatory response was seen following direct DNA injection, whereas mild inflammation was seen with either viral vector. To date, direct injection of plasmid DNA has been shown to be highly effective only in skeletal and cardiac muscle. Its effectiveness may depend on features unique to the muscle fiber.

**DNA-Coated Gold Particles.** Plasmid DNA can be affixed to gold particles (approximately 1 micron in diameter) and then "shot" into superficial cells. The DNA is coprecipitated onto the gold particle and then propelled from a mylar sheet using an electric spark or pressurized gas as the motive force. This so-called gene-gun can be used to accelerate the DNA-coated particles into superficial cells of the skin (epidermis) or into skin tumors (melanomas). Gene expression lasts only a few days, which may be more a function of the cells targeted (e.g., skin cells that are sloughed) than the method of delivery. In animal models, gene-gun delivery of DNA vaccines is highly effective (Fynan *et al.*, 1993). Gene-gun delivery is ideally suited to

gene-mediated immunization, where only brief expression of antigen is necessary to achieve an immune response.

Because of the limited depth of DNA penetration, this technique is limited to surface cells that can be accessed directly. Furthermore, since the epidermal layers of the skin are rich in antigen-presenting cells, they are a preferred target for vaccination. The simplicity, safety, and technical ease of preparation of this DNA transfer system make its large-scale application more feasible than available viral DNA delivery systems.

**Liposomes.** Liposomes have been used extensively as a technology for delivering drugs experimentally to the interior of cells. The premise is that by surrounding hydrophilic molecules with hydrophobic molecules, agents otherwise impermeable to cell membranes might be escorted into the cell. Potential advantages of such a delivery system include targeting drugs to an intracellular location and reducing toxicity.

The basic challenge in *in vivo* gene therapy is to deliver a transgene, a large hydrophilic molecule, across the plasma membrane and into the nucleus where it can access the cell's transcription machinery. Liposome delivery technology appears well suited to this task, although it has not proven to be as efficient as hoped.

Liposomes are either unilamellar or multilamellar spheres that are manufactured using a variety of lipids. Their structure can be influenced by choice of lipid composition and manufacturing process. Proteins and other nonlipid molecules can be incorporated into the lipid membranes. For convenience, liposomes are classified as either anionic or cationic, based on their net negative or positive charge, respectively.

**Anionic Liposomes.** The first *in vivo* delivery of genes using liposomes was reported by Nicolau and colleagues (1983), who encapsulated a DNA transgene coding for insulin into anionic liposomes and injected the complex into rats. The transfected rats had increased circulating levels of insulin and decreased blood glucose concentrations.

In spite of this early success, there are significant drawbacks to the use of anionic liposomes for delivering DNA. These structures, when given intravenously, primarily target the reticuloendothelial cells of the liver, making them of little use for other cell targets. Because the substance to be delivered must be encapsulated within the liposomes, the manufacturing process is complex. Also, most DNA constructs necessary for gene therapy are large compared with the liposome, so that encapsulation efficiency is very low, probably prohibitively so for practical applications.

Various proteins can be inserted into the external layer of liposomes to alter their *in vivo* behavior, including cell-selective delivery. This approach can enable liposomes given intravenously to evade the reticuloendothelial system. Protein ligands or antibodies to cell surface molecules incorporated into the liposome surface also can target liposomes to specific cell surface receptors on desired cell populations (Wu and Wu, 1987). Although promising, these strategies have not yet been applied successfully to gene therapy.

**Cationic Liposomes.** Felgner and co-workers (1987) synthesized cationic liposomes and demonstrated that they would avidly and efficiently bind nucleic acids (which are anionic) by electrostatic interactions upon simple incubation of liposomes with nucleic acids at room temperature for brief periods. The DNA or RNA complexed to cationic liposomes readily entered cells in culture without perceptible injury to the cells. A diagram illustrating the presumed mechanism for cationic liposome-plasmid transfection is given in Figure 5-3.

*In vivo*, cationic liposomes have properties quite different from those of anionic liposomes. Intravenous injection of cationic complexes has been shown to effect transgene expression in most organs if the liposome-DNA complex is injected into the afferent blood supply to the organ. In addition, the liposome-DNA complexes can be administered by intraairway injection or aerosol to target lung epithelium. In experimental animals, neither intravenous injection nor aerosol delivery of cationic liposome-plasmid complexes appears to be toxic (Brigham *et al.*, 1989).

Cationic liposomes have been used to deliver DNA gene constructs in several experimental models *in vivo*. Nabel and colleagues (1994) delivered a foreign histocompatibility gene by direct injection of plasmid-liposome complexes into tumors and showed attenuation of tumor growth in murine models. Hyde and associates (1993) showed that cationic liposome-mediated gene transfer could correct CFTR-dependent, cyclic AMP stimulated chloride conductance to

normal levels in transgenic mice homozygous for a null mutation in CFTR. Rabbits given intravenously the gene coding for the proximal enzyme in prostanoid synthesis (prostaglandin synthase) as a plasmid-cationic liposome complex produced increased amounts of endothelium-derived prostanooids in their lungs. This protected the lungs of the transfected animals from the effects of endotoxemia (Conary *et al.*, 1994).

Table 5-1 includes therapeutic goals in early stages of human application using liposome-mediated DNA delivery for gene therapy, such as delivery of foreign histocompatibility gene to tumors, delivery of the human  $\alpha_1$ -antitrypsin gene to the nasal mucosa of  $\alpha_1$ -antitrypsin-deficient patients and to subsegments of the lungs by fiberoptic bronchoscopy, and delivery of the CFTR gene to the nasal mucosa of patients with cystic fibrosis.

At present, liposome-mediated transfection offers a nontoxic, nonimmunogenic means to deliver DNA to a variety of tissues. Current usefulness of this strategy is limited by generally lower levels of gene transfer than can be obtained with viral vectors, although newer liposome formulations offer improved gene transfer efficiencies and better physical properties, *e.g.*, higher concentrations of complex without aggregation. The applications for liposomes in gene therapy likely will expand as better reagents are developed, particularly those that facilitate targeting of specific cells.

**DNA-Protein Conjugates.** Several groups have developed cell-specific DNA-delivery systems that utilize unique cell surface receptors on the target cell (Michael and Curiel, 1994).

By attaching the ligand recognized by such a receptor to the transgene DNA, the DNA-ligand complex becomes selectively bound and internalized into the target cell (Wu and Wu, 1987). These molecular conjugate vectors are attractive because they potentially offer cell-specific gene transfer without the attendant problems of viral vectors, such as replication, immunogenic viral proteins, or recombination potential. Initial model systems focused on developing effective means of attaching the DNA to the ligand using polycations, antibody-antigen complexes, and biotin-streptavidin linkers. Poly-L-lysine (PLL), a polycation, has been widely used as it can be easily coupled to a variety of protein ligands by chemical cross-linking methods. When the PLL-ligand adduct is mixed with plasmid DNA, macromolecular complexes form in which the DNA is electrostatically bound to the PLL-ligand molecules. These toroidal structures (50 to 100 nm in diameter) present ligands to the cell surface receptor that are efficiently endocytosed. The transferrin receptor (Zenke *et al.*, 1990), the asialoorosomucoid receptor (Wu and Wu, 1987), and cell surface carbohydrates (Batra *et al.*, 1994) have been used to demonstrate the potential of ligand-mediated gene delivery. The asialoorosomucoid receptor is of particular interest because it is found almost exclusively on hepatocytes and therefore might be useful in mediating gene transfer into the liver.

Early DNA-ligand complexes were inefficient for DNA transfer because most of the endocytosed complex was shuttled to the lysosomal compartment, and DNA was




Figure 5-3. Cationic liposome-mediated DNA-delivery.

Diagrammatic representation of how cationic liposome-plasmid complexes are thought to effect gene transfer to a cell. Little is known about the actual structure of the plasmid-liposome complex. Likewise, processes affecting cell entry and transport to the nucleus are yet to be clarified. The circular plasmid DNA does not readily incorporate into the host genome and does not replicate in mammalian cells; thus transgene expression apparently is episomal in nature.

## SECTION I GENERAL PRINCIPLES

then degraded. Although several agents (e.g., chloroquine) have been used to block lysosomal degradation, the efficiency of transfection is still low compared with other DNA-delivery methods. A more effective approach is to utilize the endosomal escape functions of the adenovirus. As described earlier, proteins in the adenovirus capsid promote escape of the DNA complex from the endosome prior to fusion with the lysosome. Although metabolically inactivated adenovirus theoretically could be employed to escape lysosomal targeting, the concentrations of adenovirus required to ensure colocalization of the virus and the DNA-protein complex to the same endosome are so high as to induce adenovirus-mediated cytopathic effects. Consequently, investigators have constructed physically linked complexes between the adenovirus and the DNA-ligand adduct, thereby ensuring their simultaneous delivery to each endosome and diminishing the amount of adenovirus required to escape lysosomal delivery and degradation (see Fisher and Wilson, 1994).

Two general approaches have been used to construct adenovirus-DNA-ligand complexes. Poly-L-lysine can be covalently attached to purified adenoviral particles using a water-soluble carbodiimide. This is then mixed with asialo-orosomucoid receptor-poly-L-lysine-DNA toroids to form clusters of icosahedral adenoviral particles and toroids. The size of these clusters varies from small clusters (<200 nm) with single toroids coupled to two viral particles up to large clusters (200 to 300 nm) containing more than a dozen viral particles and toroids. The composition of the clusters is governed by the amount of poly-L-lysine attached to the viral particles. These complexes achieve higher levels of hepatocyte-specific gene transfer at lower concentrations of virus than do mixtures of unlinked toroids and adenovirus (see Cristiano *et al.*, 1993).

This technology can be further improved by layering the DNA and ligand over the surface of the adenovirus to create a coated adenovirus, rather than the side-by-side (virus-toroid-virus) structures described above (Fisher and Wilson, 1994). This creates single viral particles that retain their endosomalysis ability, are coated with DNA and extend the asialo-orosomucoid receptor from the particle surface. These smaller particles (<100 nm) still retain some adenovirus receptor recognition and uptake, similar to the larger clusters above, but their smaller size may make them better able to traverse the fenestrated hepatic endothelium. The use of two reporter genes, one carried in the plasmid DNA and the other in the adenovirus genome, has allowed the simultaneous assessment of viral infectivity and efficiency of plasmid gene transfer. By decreasing the amount of adenovirus required, virus-induced cytotoxicity essentially can be eliminated. The presence of two receptor pathways for DNA entry (ligand receptor and adenovirus receptor) clearly diminishes the specificity of this DNA delivery system. The adenovirus receptor pathway can be effectively eliminated by using an antibody against adenovirus fiber protein as the means for linkage to DNA (Michael and Curiel, 1994), an approach that obliterates the ability of the virus to bind adenovirus receptors but not its ability to mediate lysosomal escape. Further refinements, such as the use of purified endosomalytic proteins rather than intact adenovirus particles, should enhance the utility of this type of DNA-delivery system (Seth, 1994).

## DISEASE TARGETS FOR GENE THERAPY

## Organ-Directed Gene Therapy

**Liver.** Liver-directed gene therapy has emerged as an important model for the treatment of inherited and acquired disorders. The liver can be afflicted with a variety of metabolic, infectious, and neoplastic diseases for which specific molecular interventions can be envisioned. For example, gene transfer methods might be used to deliver interferon alfa for the treatment of hepatitis B, cytotoxic therapy for hepatic carcinomas, or to provide a missing gene to correct an inherited metabolic defect. Potential applications are made more feasible by the existence of multiple methods for targeting gene transfer to the liver. Molecular conjugates, adenoviral vectors, liposomes, and retroviral vectors all have been used for hepatocyte gene transfer. For *in vivo* gene transfer, the liver is accessible by a number of routes, including direct injection and intravenous and intrabiliary administration of vectors. *Ex vivo* strategies can be implemented by partial surgical resection of the liver, isolation of hepatocytes, and *in vitro* hepatocyte transduction. The genetically modified cells can be reimplanted into the liver.

**Familial Hypercholesterolemia.** Patients with familial hypercholesterolemia have an inherited deficiency of the low-density lipoprotein (LDL) receptor and, as a consequence, develop extremely high plasma levels of cholesterol and arteriosclerosis at a very early age (see Chapter 36). The genetic defect manifests itself as a diminished ability of the liver to clear LDL particles from the blood, and serum lipid levels provide a convenient marker of the disease. Although pharmacological interventions have had limited success, correction of the hepatic dysfunction by orthotopic liver transplantation leads to normalization of blood lipid levels and slowing of arterial disease progression. This clinical observation suggested that if the liver could be genetically modified to express the LDL receptor, the same benefits might be achieved. The Watanabe heritable hyperlipidemic rabbit has served as an ideal animal model to demonstrate that this approach could lead to persistent reductions in serum LDL (see Figure 5-4) (Chowdhury *et al.*, 1991). Several patients now have been treated in a clinical trial using an *ex vivo* DNA delivery approach and retrovirus to introduce the LDL receptor gene into hepatocytes isolated from the patients following partial hepatectomy (Grossman *et al.*, 1994). This study demonstrated the feasibility, safety, and potential efficacy of *ex vivo* hepatic gene therapy.

The overall success of DNA transfer into hepatocytes will be determined by several factors that currently are unknown. In particular, very little is known about the normal turnover of hepatocytes and how this will relate to the persistence of genetically modified cells. An immune response to the therapeutic gene product, a potential problem for all gene therapies of deficiency states, has not been observed to date. The potential for the therapeutic gene product to serve as a neoantigen may vary among different types of deficiencies and depend on the nature of the protein product and whether the deficiency arises from total absence of the protein or from expres-



Transf into p vein

Figure 5- transfer oj

The V an id LDL expr ather trans tomy The r enzy in tis expr stabl vein proce the s

sion of a above (G metabolic approach in the fut munogen

Lung. familial strategi both the Familia quence dogeno ders the released is avail ease. Ti tively to 1994). deficie Cystic herited most o




Figure 5-4 An animal model for *ex vivo* retrovirus gene transfer of the low density lipoprotein (LDL) receptor.

The Watanabe heritable hyperlipidemic (WHHL) rabbit is an ideal animal model of the inherited deficiency in the LDL receptor. Lacking the LDL receptor normally expressed in hepatocytes, these animals rapidly develop atherosclerosis. The feasibility of *ex vivo* retrovirus gene transfer is demonstrated by this model. A partial hepatectomy is performed, removing up to one-third of the liver. The resected portion of the liver is perfused *ex vivo* with enzymes to disperse the hepatocytes, which are then placed in tissue culture and exposed to recombinant retrovirus expressing the LDL receptor. Hepatocytes containing the stably integrated viral DNA are injected through the portal vein back into the liver where they take up residence. This procedure now has been conducted in human patients with the same disorder.

sion of a dysfunctional (mutated) protein. The clinical trial cited above (Grossman *et al.*, 1994) provides the first example of sustained metabolic correction of a genetic defect. The *ex vivo* gene transfer approach likely will be replaced by *in vivo* gene transfer strategies in the future, once problems of vector efficacy, persistence, and immunogenicity are overcome.

**Lung.** The two most common inherited lung diseases are familial emphysema and cystic fibrosis. Gene therapy strategies have been directed toward the amelioration of both these diseases.

**Familial Emphysema.** Familial emphysema is a consequence of a defect in the gene encoding the principal endogenous antiprotease,  $\alpha_1$ -antitrypsin. This deficiency renders the lungs vulnerable to injury by neutrophil proteases released at sites of inflammation. The  $\alpha_1$ -antitrypsin protein is available clinically and is given to patients with the disease. The human gene has been cloned and delivered effectively to the lungs of experimental animals (Canonico *et al.*, 1994). Initial studies in human beings with  $\alpha_1$ -antitrypsin deficiency have been approved by the NIH (see Table 5-1). **Cystic Fibrosis.** Cystic fibrosis is the most common inherited disorder in the Caucasian population, and because most of its morbidity and mortality stems from pulmonary

manifestations, it is an ideal model for gene therapy of inherited lung disease. *Ex vivo* gene transfer strategies are not a viable option in the lung. Removal and reimplantation of airway cells is not technically feasible for therapy. Because the target cells in the airway turn over very slowly, retroviral gene transfer, which requires cell division, is very inefficient. In contrast, adenoviral vectors are uniquely suited for this application, as adenovirus has a known tropism for respiratory epithelium. A major potential drawback to the use of adenovirus is the transient nature of gene expression and uncertainty as to whether an adenovirus-induced inflammatory response will allow readministration of the vector. Additionally, airway neutrophils and secretions may decrease transfection efficiency. Nonetheless, a major effort has been launched to develop adenoviral vectors suitable for transducing airway epithelia *in vivo*.

Human studies have been conducted in which adenovirus encoding the cystic fibrosis transport regulator (CFTR) was administered into the nasal epithelium of patients with cystic fibrosis (Zabner *et al.*, 1993). With relatively low doses of virus, normalization of chloride conductance was observed. The major current disadvantage of adenovirus as a vector has been the host response to virally encoded proteins. An inflammatory response to adenovirally transduced cells has been observed in a variety of animal models and in patients, because the vector contains most of the wild-type viral genome. Although the virus has been rendered replication-incompetent by deletion of a subset of viral genes, it still directs the virally transduced cell to synthesize immunogenic viral proteins. Newer versions of the recombinant adenoviral vector may overcome this limitation by attenuating the expression of adenoviral proteins. Engelhardt and colleagues (1994) have shown that alterations of the adenoviral genome in addition to E1 and E3 deletions can decrease the inflammatory response following gene transfer. A temperature-sensitive E2 mutant (ts 125) that preferentially grows at 32° C is introduced into the viral genome so that, when the virus is used to infect cells at 39° C, the mutant E2 protein is less effective in transactivating downstream adenoviral genes that presumably are responsible for inducing the host inflammatory response. In practice, the virus can be propagated in permissive cells (293 cells) at 32° C *in vitro*, and then used to transduce cells *in vivo* at 37° C. Following *in vivo* transduction, the virus is replication-defective (E1 deleted) and less efficient in the synthesis of adenovirus proteins at the elevated body temperature. This results in less inflammation and prolonged transgene expression. Further improvement in the design of adenoviral vectors is under development, including mutations that will remove all or part of the E4 region.

At present, the number of patients treated in all cystic fibrosis gene therapy trials is too small to draw any meaningful conclusions as to efficacy. However, the principles of airway delivery of genetic material are now well established. Future generations of genetic DNA transfer systems, including the adeno-associated virus and liposome systems discussed earlier, likely will offer meaningful benefits not only for cystic fibrosis but also for a variety of lung disorders.

**Vasculature.** The blood vascular system has been the target of several gene transfer experiments that have demon-

strated the therapeutic potential of gene delivery into this tissue. Both the endothelial cells that line the blood vessels and the smooth muscle cells beneath the endothelium have attracted much attention because of their role in atherosclerosis and the prospect that they might be used to deliver transgene products into the bloodstream. Genetic alterations of these cells might be useful to alter or prevent the process of atherosclerosis, or to deliver vasodilating agents locally or, alternatively, to provide local delivery of anticoagulants.

**Ex Vivo Strategies.** Initial experiments focused on *ex vivo* gene transfer methods. Wilson *et al.* (1989) demonstrated that canine endothelial cells could be genetically modified *in vitro* by retroviral gene transfer and then transplanted back into the dog as a Dacron® vascular implant seeded with the modified endothelial cells demonstrating transgene expression for over 5 weeks. In another study, cultured endothelial cells from a Yucatan minipig were transduced *in vitro* with replication-defective retrovirus prior to reintroduction into an artery by means of a special double-balloon catheter. By occluding blood flow to a denuded segment of the artery, the catheter provided a temporary protected space where the modified endothelial cells could reattach to the vessel wall (Nabel *et al.*, 1989).

**In Vivo Strategies.** *In vivo* gene delivery obviates the need for syngeneic cells and will be required for therapeutic applications such as the treatment of atherosclerosis. *In vivo* gene transfer has been achieved using the double-balloon catheter approach with instillation of the DNA delivery system into the protected space of the temporally occluded vessel. Retroviruses, liposomes, and adenoviral vectors all have been used to target a specific site within a large vessel using this approach.

**Atherosclerosis.** A variety of genes have been expressed by *in vivo* gene transfer for the purpose of developing useful clinical applications as well as for developing models of pathogenic mechanisms. Vascular cell proliferation and extracellular matrix protein deposition are associated with atherosclerotic narrowing of arteries. Factors that potentially contribute to this process can be studied by overexpressing their genes in arterial segments. For example, when acidic fibroblast growth factor (FGF-1) is ectopically expressed in porcine arteries, the vessel wall becomes thickened (intimal hyperplasia) as a result of smooth muscle cell proliferation (Nabel *et al.*, 1993c). In addition, new blood vessels form within the arterial wall as a result of endothelial cell migration and growth. In contrast, when TGF- $\beta$ 1 is expressed ectopically in the vessel, extracellular matrix synthesis and intimal thickening result (Nabel *et al.*, 1993a). Platelet-derived growth factor B also has been shown to induce intimal hyperplasia following *in vivo* gene transfer (Nabel *et al.*, 1993b). These experimentally induced changes in the vessel wall mimic the changes found in atherosclerotic lesions. Gene transfer thus provides a useful tool to study the effects of agents that may be part of a complex disease process.

**Autoimmune Vasculitis.** In an attempt to model another arterial disease, autoimmune vasculitis, a foreign histocompatibility gene was delivered to vessel walls by liposome-mediated gene transfer, resulting in a focal immune response at the site of gene transfer that histologically resembles Takayasu arteritis (Nabel *et al.*, 1992). These experiments demonstrate that models of human disease can be developed by introducing specific molecular changes in the blood ves-

sel. These models of arterial disease may be useful in evaluating agents that can block these processes and alter the progression of the disease.

**Prevention of Restenosis.** In addition to understanding the process by which vascular diseases develop, gene transfer techniques have been developed to treat these diseases. For example, atherosclerotic coronary arteries often can be treated by balloon angioplasty. The narrowed segment of the atherosclerotic vessel is mechanically dilated by the insertion and inflation of a balloon catheter. Although it provides long-term benefits for many patients, this procedure has a high rate of vessel closure (restenosis) within weeks after the dilation. Restenosis occurs, in part, as a result of smooth muscle hyperplasia. Introduction of an adenoviral vector encoding thymidine kinase followed by systemic administration of ganciclovir blocked arterial hyperplasia in an animal model of restenosis (Ohno *et al.*, 1994).

## Cancer Gene Therapy

Cancer gene therapies have employed several strategies that rely on unique molecular targets found in cancer cells. Activated oncogenes or mutated tumor suppressor genes are common features of human malignancies. For instance, mutations in the Kirsten-*ras* oncogene, which occur commonly in adenocarcinomas of the lung, are associated with tobacco consumption and may contribute to tumor progression. Mutations in tumor-suppressor-genes also occur frequently in human cancers. The retinoblastoma p53 gene, which encodes the nuclear protein p53 that regulates cell growth, is the most frequently altered gene in cancer; defects in the function of this suppressor gene and its gene product contribute to unregulated cellular proliferation.

Molecular processes that regulate cell growth, although fundamental to tumor progression, are in general difficult to target with current gene transfer methods for several reasons. Particular oncogenes, such as Kirsten-*ras*, are commonly but not uniformly present in all tumors, even of a given histological type. More important, interruption of a specific oncogene's function or restoration of tumor suppressor gene function would have to be done in every malignant cell, since untreated cells would readily divide. Because most cancers exert their morbidity and mortality through metastatic spread, one is faced with not only targeting every cancer cell but also targeting cancer cells in widespread anatomical locations (bone, liver, lung, brain, *etc.*). Furthermore, many lesions are microscopic metastatic deposits, undetectable by current diagnostic imaging methods. This makes it difficult to assess the efficacy of a new gene transfer method because, in the course of the long follow-up required, it may be unclear whether failure of the treatment resulted from inefficient gene transfer or from any of the many other events that could contribute to ineffectiveness of cancer therapy.

Many tumors acquire a series of genetic defects as they progress. In addition, some tumors arise as a consequence of mutations that result in a gain of function, not loss of function, and thus require ablation of the new activity. For example, chronic myelogenous leukemia occurs as the result of expression of a new chimeric gene product.

Because current gene transfer techniques are unable to achieve a satisfactorily high level of transfer efficiency in an *in vivo* setting, alternative strategies that do not require 100% efficiency of gene transfer have been sought. Two general approaches have evolved that may be effective when only a minority of the tumor cells are transduced: (1) cell-targeted suicide, achieved by directing the synthesis of a toxic metabolite that can permeate the tumor microenvironment, and (2) engineering an immune response to the tumor cells by ectopic cytokine expression or other means for immune recognition or activation.

**Cell-targeted Suicide.** Conversion of a prodrug to a toxic metabolite by genetically engineering the tumor cell is an attractive way to create an "artificial" difference between normal and neoplastic tissue. This can be achieved by the expression of a gene that confers a dominant, negatively selectable phenotype to the cancer cell, such as cell death imparted by expression of a drug-metabolizing enzyme. A variety of enzymes are capable of performing such a function, and typically kill cells by activation of a relatively nontoxic prodrug to a cytotoxic form (Table 5-2). Greater selectivity in killing malignant cells will be obtained if the transferred gene is not normally found in human beings (e.g., HSV-thymidine kinase), rather than by overexpressing an endogenous gene (e.g., deoxycytidine kinase).

Insertion of the HSV-thymidine kinase (HSV-TK) gene into malignant cells in conjunction with the systemic administration of ganciclovir has become a prototypic gene therapy system that uses the enzyme-prodrug approach. Many investigators have shown that the expression of the HSV-TK gene confers a negative selectable phenotype to cancer cells both *in vitro* and *in vivo*.

Moolten (1986) demonstrated acquired ganciclovir sensitivity in a murine sarcoma cell line transduced with a retroviral vector that produces HSV-TK. The transduced sarcoma tumor cells were 200 to 1000 times more sensitive to ganciclovir than control tumor cells. This finding has been reproduced in several rodent and human cancer model systems including lung cancer, mesothelioma, hepatocellular carcinoma, leukemia, melanoma, and CNS tumor models. The efficacy of this approach varies significantly and may be due to a variety of factors including promoter function, target cells studied, and efficiency of transduction.

The tumoricidal activity of the HSV-TK/ganciclovir system is due to several factors. In dividing cells, the phosphorylated ganci-

clovir inhibits DNA synthesis. This effect is not confined to cells that are directly transduced with HSV-TK, as neighboring cells are also affected. This phenomenon, which likely occurs as a result of several mechanisms, has been termed the "bystander effect" and has been observed in several tumor types, including CNS tumors (Freeman *et al.*, 1993). Transfer of the phosphorylated ganciclovir between cells ("metabolic cooperation") via gap junctions has been proposed as a possible mechanism. Phagocytosis by neighboring cells of ganciclovir phosphate-containing apoptotic vesicles (from dying transduced cells) also has been proposed. Immune-mediated processes also may account for significant killing of non-transduced cells. In one report, anti-tumor immunity was observed following TK-mediated killing of experimental brain tumors. Whether the tumor immunity is TK dependent, or merely a manifestation of inherent tumor cell immunogenicity, has yet to be established in this rodent model (Barba *et al.*, 1994).

More recently, adenovirus vectors have been used for gene transfer of HSV-TK. Chen *et al.* (1994a) demonstrated regression of experimental gliomas following *in vivo* adenovirus-mediated gene transfer and ganciclovir treatment. The tumor deposits were not completely eliminated by this treatment, however. Tumor cells close to the injection site were more readily transduced than were those distant, as judged by parallel marker gene transfer experiments. Furthermore, these more distant cells escaped ganciclovir toxicity because of a diminished bystander effect attributed to a paucity of gap junctions in the rodent brain tumor cell line employed. This limitation potentially can be overcome in the clinical setting by more precise stereotactic treatment planning (aided by MRI and PET studies) and by multiple tumor injections.

Other approaches have focused on introducing genes that stimulate an immune response to the tumor. Although some have argued that tumor growth occurs as a result of im-

**Table 5-2**  
**Enzyme-Prodrug Combinations for Cancer Gene Therapy**

GENE	PRODRUG
HSV thymidine kinase (HSV-TK)	Ganciclovir Acyclovir
VSV thymidine kinase	Ara-M
Deoxycytidine kinase	Ara-C Fludarabine 2-Chlorodeoxyadenosine Difluorodeoxycytidine
Cytosine deaminase	5-Fluorocytidine
Nucleoside phosphorylase*	MeP-dR

\*Nucleoside phosphorylase is encoded by the *E. coli* *DeoD* gene, the coding sequence used in this therapeutic strategy.

*Key:* HSV, herpes simplex virus; VSV, vesicular stomatitis virus; Ara-C, cytosine arabinoside or cytarabine; Ara-M, 6-methoxypurine arabinoside; MeP-dR, 6-methylpurine-2'-deoxyriboside.

mune stimulation, there is little direct evidence to support this hypothesis in most human tumors. Rather, there is a growing body of evidence that suggests that tumor cells express unique determinants that are capable of being recognized by the immune system.

**Ectopic Cytokine Expressions.** A variety of cytokines have been shown to decrease tumor growth when ectopically expressed on tumor cells or in their microenvironment (Tepper and Mule, 1994). Tumor cells engineered to secrete certain cytokines have been observed to be less able to form tumors when implanted in syngeneic hosts, whereas their *in vitro* growth is unaffected, suggesting that host factors are induced in response to the cytokines that decrease tumorigenicity. Some immunostimulatory agents do not alter the growth rate of the tumor initially, but lead to immunity against tumor growth if the animal is later challenged with wild-type tumor cells. It is apparent that genetically engineered tumor cells elicit a variety of host immune responses depending on the immunomodulatory agent employed. For example, interleukin-4 (IL-4) secretion by a tumor cell elicits a potent local inflammatory response without any effect on distant tumor cells or tumor cells administered at later times. In contrast, granulocyte-macrophage colony stimulating factor (GM-CSF) has little effect on the tumorigenicity, but evokes a potent anti-tumor immunity (Dranoff *et al.*, 1993). In many instances, multiple immune effects are initiated by tumors expressing immunomodulatory agents. This is seen in tumors secreting interleukin-2, where the tumor becomes infiltrated with T lymphocytes, activated macrophages, natural killer cells, neutrophils, and eosinophils. Additionally, a cytokine may have different effects in different tumor types. For example, interleukin-6 can have direct antiproliferative effects, recruit natural killer cells, or serve as an autocrine growth factor, depending on the type of tumor investigated. In many circumstances, it is difficult to distinguish the effects that are induced by the cytokine from the effects mediated secondarily by the other immune effector cells. This has led to a rather empiric approach to cytokine-based cancer gene therapy. The cytokines interleukin-1, -2, -4, -6, -7, and -12, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interferon gamma, G-CSF, GM-CSF, and lymphocyte co-stimulatory molecules, all have been shown to induce immune destruction of tumor cells in model systems. Of these, interleukin-2, interleukin-4, TNF- $\alpha$ , interferon gamma, and GM-CSF have been entered into clinical trials using tumor cells genetically engineered to secrete the cytokine (Tepper and Mule, 1994; *see also* Chapter 52).

**Immune Enhancement.** Other approaches aimed at increasing the immune response to cancer cells have been developed. One such approach is to express highly immunogenic molecules on the surface of cancer cells, such as expression of allotypic MHC antigens. Alternatively, rather than express an exogenous "rejection" antigen, tumor cells may be modified so that the endogenous weakly immunogenic tumor-associated antigens are better recognized. It has been long known that additional "co-stimulatory" pathways distinct from the T-cell receptor are needed to achieve T-cell activation (*see Chapter 52*). The molecules B7-1 and B7-2 stimulate one such pathway. The B7's, whose expression normally is limited to antigen-presenting cells and other specialized immune effector cells, engage specific receptors (CD-28 and CTLA-4) on the T-cell surface in concert with antigen binding to the T-cell receptor. Subsequently, T-cell activation, cell proliferation, and cytokine production ensue, and can lead to the elaboration of antitumor immunity. The absence of a costimulatory signal at the time of T-cell receptor engagement is not a neutral event; rather, it results in the development of tumor-specific anergy, not mere failure to activate the T cell (*see Chapter 52*). Thus, the simple presence of antigens in tumor cells would be expected to produce an immune-tolerant state rather than an immune-responsive state if costimulatory events do not take place. In effect, this is what is seen in most clinical situations where human tumors grow apparently unimpeded by host immune mechanisms. When some tumor cells are provided with costimulatory molecules, effective T-cell activation takes place. This has been demonstrated by ectopic expression of B7 on tumor cells, which then are used to stimulate an immune response to the parental tumor cell line.

Several investigators have employed this experimental approach to demonstrate that tumors endowed with B7 co-stimulation ability are able to activate the host immune system to recognize and eradicate tumor cells. Chen *et al.* (1994b) coexpressed B7 and the human papilloma virus E7 rejection antigen in K1735 murine melanoma cells. When injected into syngeneic mice, these cells (E7+B7+) induced a B7-dependent immune response, which resulted in tumor regression. In contrast, E7+B7- tumor cells did not induce an antitumor response. Furthermore, once primed by E7+B7+ cells, mice were capable of rejecting subsequently injected E7+B7- tumor cells. However, these mice were not able to reject the parental tumors, which were E7-. This study also revealed that immune rejection required the presence of CD8+ but not CD4+ T cells.

A similar study by Li *et al.* (1994) suggested the contribution of both CD8+ and CD4+ cells in tumor immunity. A K1735 cell line expressing both MHC class I and II molecules was transfected to express both B7-1 and p97 antigen. The p97 antigen is known to be very immunogenic and to stimulate the production of CD4+ clones specific for this antigen. B7 expression, when coexpressed

with p97, supported the expansion of both the CD8+ cytotoxic T lymphocytes and CD4+ lymphocytes. Furthermore, while CD8+ T cells were the most important effector cells, both cell types were necessary to eliminate established tumor nodules. Clinical experience clearly demonstrates that the mere presence of tumor-associated antigens does not induce an immune response. The implication of these studies is that the ineffectiveness of tumor antigens may be overcome by expressing B7 on the tumor cells. In these and other experiments, the presence of MHC class II molecules on the tumor cell surface, in addition to class I molecules, contributes to the overall immune response, and in particular the CD4+ component of the response. Because most human tumors do not express class II molecules, an effective CD4+ T-cell response may require additional intervention beyond B7 expression. Consequently, providing cytokine stimulation that can provide this effect may be of merit.

The foregoing experiments were performed with what is now known as B7-1. Additional experiments have shown that other molecules (B7-2, and perhaps others) are able to bind the same T-cell receptors as B7-1 (CD-28 and CTLA-4) and activate T-cell co-stimulatory pathways. The differential role of these similar ligands is only beginning to be explored. The temporal course and relative level of their expression are clearly different, as is their ability to be differentially regulated by the same stimuli. A similar level of complexity is emerging for the B7 receptors CTLA-4 and CD-28. Although the differential role of these molecules as they relate to the normal function of the immune system is beginning to be understood, which of the B7's will provide the most effective route to antitumor immunity is unknown (see Chapter 52 for a review of cellular mechanisms of immune enhancement and suppression).

T-cell activation, although critically dependent on TCR and co-stimulation pathways, also may be supported by additional functions normally provided by the antigen-presenting cell. Interleukin-12 (IL-12) is secreted by antigen-presenting cells and functions by binding to specific receptors on T cells and natural killer cells. IL-12 induces the production of interferon gamma and enhances the production of a cytotoxic T-lymphocyte response. In one murine tumor model, IL-12, when produced in the microenvironment of a developing tumor nodule, delayed development of detectable tumor nodules (Ohno *et al.*, 1994). IL-12 in this model did not lead to protective antitumor immunity, *i.e.*, tumor development was delayed, but not entirely prevented. Interestingly, the B16-derived BL-6 melanoma cell line is poorly immunogenic yet was able to provoke T-cell activation when supported by this exogenous cytokine. Other investigators have reported that B16 tumor cell lines are not rendered capable of inducing an immune response when transduced to express B7-1. The fact that IL-12 can induce immune responsiveness to a tumor when B7-1 could not suggests that these immunomodulatory molecules may provide different functions. Recently, it has been shown that B7-1 and IL-12 can act in synergy to induce T-cell proliferation and cytokine (interferon gamma and TNF- $\alpha$ ) production (see Chapter 52).

Not all of the obstacles to genetically engineered tumor vaccines have been fully identified. Immune tolerance of tumor cells may arise by many mechanisms, including tumor cell secretion of immunosuppressive agents (*e.g.*, TGF- $\beta$ ), and other means to overcome tolerance will need to be devised. Nonetheless, the ectopic expression of genes in cancer cells is a very flexible and powerful tool that likely will improve upon the current therapeutic approach of systemically administered antineoplastic agents (see Chapter 51).

## Gene Transfer into Hematopoietic Stem Cells

Gene transfer into bone marrow stem cells has been proposed for a variety of inherited and acquired disorders. These include inherited defects in cells produced by the bone marrow (*e.g.*, sickle cell disease, thalassemias, chronic granulomatous disease, and several lymphocyte disorders), as well as acquired illnesses in which marrow-derived cells are secondarily involved (*e.g.*, acquired immunodeficiency syndrome [AIDS] and chemotherapy-induced myelosuppression). The long-term repopulating potential of the bone marrow stem cell also makes it a potentially useful agent for the production and delivery of proteins normally produced by nonhematopoietic cells (*e.g.*, coagulation proteins). The development of bone marrow transplantation has provided substantial precedence for this approach. The growing number of diseases that can be treated effectively by bone marrow transplantation demonstrates the therapeutic efficacy of providing a "corrected" marrow. For example, severe  $\beta$ -thalassemia (an inherited defect in hemoglobin biosynthesis) can be cured by transplantation of bone marrow from a normal donor. The gene therapy equivalent would be to correct the patients' own marrow rather than substitute a "foreign" normal marrow. Because bone marrow can be removed easily and reimplanted, it provides an ideal setting for *ex vivo* gene therapy strategies. The ultimate goal is to be able to transfer genes into hematopoietic stem cells and allow these cells to reconstitute the bone marrow with the selective expression of the transferred gene in a specific hematopoietic cell lineage.

**Immunodeficiency Disorders.** Gene therapy offers potential treatments for a variety of immunodeficiency disorders. As noted earlier, the first disorder to be treated by gene therapy was a form of severe combined immunodeficiency (SCID) caused by the deficiency of the enzyme adenosine deaminase (ADA). In children with this disorder, the absence of ADA leads to an accumulation of deoxyadenosine triphosphate, which is toxic to lymphocytes; patients develop recurrent life-threatening infections due to defective cell-mediated and humoral immune responses. Current standard therapy includes bone marrow transplantation from an HLA-matched sibling. Although less effective, intravenous replacement of ADA is used in patients who lack a suitable marrow donor. While the first clinical trial of gene therapy for ADA deficiency resulted in clinical improvement, it has not provided a permanent cure. The first patients were treated by repeated gene transfer

into peripheral blood lymphocytes that had been isolated by apheresis. A preferable approach would be to insert the ADA gene into pluripotent hematopoietic stem cells that could reconstitute the immune system with a complete repertoire of immune cells. Such approaches are under development. It has been demonstrated recently that long-term correction of ADA deficiency can be achieved (albeit at low levels) in a rhesus monkey model (Van Beusechem *et al.*, 1992; Bodine *et al.*, 1993).

Leukocyte adhesion deficiency (LAD) is another inherited disorder that results from defective leukocyte function. Patients with this disorder lack cell surface glycoproteins that mediate cell-cell interactions necessary for immune function. Krauss *et al.* (1991) have developed a retrovirus-mediated gene therapy strategy for the treatment of these disorders.

**Lysosomal Storage Diseases.** Lysosomal storage diseases result from the lysosomal accumulation of cellular material that cannot be degraded, or degraded material that cannot be further processed. Over fifty such disorders are known in human beings and animals. In these disorders, the absence of a particular lysosomal enzyme involved in the breakdown of glycolipids and sphingolipids leads to an increase in lysosome size and number, and secondary derangement of cellular function. The recessively inherited Gaucher disease is typical of the storage diseases in many aspects. Glucosylceramide, a lipid, accumulates in macrophages of affected individuals due to a deficiency of glucocerebrosidase. This results in enlargement of the liver and spleen, destructive bone lesions, and variable central nervous system dysfunction. Several genetic defects are known and there is significant variation in the phenotypic appearance of the disease within a given genotype (*see* Neufeld *et al.*, 1991).

The observation that cultured fibroblasts from an affected individual could be "cross-corrected" by coculture with normal cells that secrete the enzyme led to the development of replacement therapy. Although intravenous administration of the deficient enzyme is not highly effective in patients, replacement therapy has demonstrated that enzyme-deficient cells are able to take up exogenously produced enzyme. Alternatively, transplantation of an affected patient with normal bone marrow cells can offer clinical improvement in some cases of lysosomal storage disease. The transplanted hematopoietic cells are able to deliver normal enzyme to affected tissues. Cells capable of making the normal enzyme can transfer the secreted enzyme to a recipient cell by a receptor-mediated endocytosis pathway or via direct contact-mediated transfer. This capacity for cell-to-cell transfer of lysosomal enzymes via receptor-mediated endocytosis has been demonstrated in a number of animal models, including a murine model of  $\beta$ -glucuronidase deficiency (Bou-Gharios *et al.*, 1993) and a feline model of  $\alpha$ -mannosidosis (Walkley *et al.*, 1994). Although

bone marrow transplant may be therapeutically useful in some circumstances, its utility is diminished by the availability of suitable marrow donors and the immunosuppressive risks associated with transplanting allogeneic bone marrow. Gene transfer methods that may overcome these shortcomings are being developed. By engineering the patient's marrow to express the desired enzyme, the patient's own leukocytes could deliver normal enzyme. In one proposed treatment strategy, bone marrow would be harvested from the patient and the "corrected" gene inserted in *in vitro* culture. Reinfusion of the manipulated marrow cells would lead to the long-term replacement of the enzyme without the need for immunosuppressive agents. Several investigators have effected retrovirus-mediated gene transfer into marrow cells from animals and human beings and demonstrated that long-term production of the desired enzyme is achievable.

**Drug Resistance Genes in the Treatment of Cancer.** The mechanisms by which cancer cells are able to survive the cytotoxic effects of chemotherapy are well described for a number of chemotherapeutic agents. These mechanisms include the expression of genes that are able to inactivate or eliminate the toxic drug (*see* Chapter 51). Although these genes currently serve to limit the effectiveness of many chemotherapy regimes, it is possible that they might be redeployed to have the opposite effect, that is, to protect normal tissues from the toxic effects of chemotherapy. One gene in particular has received much attention in this regard, the multidrug resistance (MDR-1) gene encoding the multidrug transporter protein (also known as P-glycoprotein). This transmembrane protein is capable of pumping a wide variety of chemotherapeutic agents (e.g., adriamycin, vinca alkaloids, epipodophyllotoxins, and taxol) and other drugs out of cells, thus protecting them from the agents' toxic effects (Gottesman *et al.*, 1994). Many cancers display a dose-dependent sensitivity to chemotherapy, whereby larger doses of chemotherapy lead to greater tumor regression and improved survival (*see* Chapter 51). This is best illustrated by testicular cancers, which are highly curable when treated aggressively. Unfortunately, toxicity to normal tissues, especially the bone marrow, limits the use of larger doses of chemotherapy in many cancers. To overcome this, autologous bone marrow transplantation has been employed to rescue the bone marrow from the toxic effects of high-dose chemotherapy. In some cancers (e.g., breast cancer and testicular cancer), relapse after standard therapy can be treated by harvesting uninvolved normal bone marrow prior to high-dose chemotherapy. The stored autologous marrow is then reinfused to rescue the patient from therapy-induced marrow ablation. Such high-dose chemotherapy with autologous bone marrow transplantation is now standard therapy for relapsed testicular cancer. Capitalizing on this concept, a gene therapy-based strategy has been proposed whereby

the MDR-1 gene would be used to render the bone marrow resistant to the toxic effects of the chemotherapy (Gottesman *et al.*, 1994).

Although gene transfer into marrow stem cells leads to transgene expression in only a few percent of hematopoietic cells, successive cycles of chemotherapy can be used to enrich for transduced marrow cells. This approach may be applied to cancers that demonstrate a steep dose-response to chemotherapy and where myelosuppression is the dose-limiting toxicity.

### Gene Therapy for Infectious Diseases.

The failure of conventional antibiotics to treat many types of serious pathogenic agents effectively, most notably the human immunodeficiency virus, and the availability of unique molecular targets in these pathogens have encouraged the exploration of gene therapies for infectious diseases.

**AIDS.** Nabel *et al.* (1994) and Malim *et al.* (1992) have used a dominant negative mutant protein in designing a gene transfer strategy for the treatment of AIDS. The rev protein, produced by the human immunodeficiency virus, is a regulatory protein necessary for viral replication. It binds to a specific viral RNA motif (rev response element, RRE) and promotes the synthesis of new viral proteins. Studies in experimental models have shown that by introducing a mutant rev gene, the HIV-infected cell produces an altered rev protein. This protein, called Rev M10, is capable of binding the same motif as the normal rev, but is not functional in promoting the synthesis of new viral proteins. Consequently, Rev M10 competitively inhibits the activity of the normal rev protein and ultimately attenuates HIV replication.

**Immunization.** By an entirely different approach, gene transfer can be employed to drive the synthesis of an

antibody with predetermined specificity. This would eliminate the need to rely on a variable or unpredictable immune response to a vaccine (particularly in immune-compromised patients) and could be used to direct the synthesis of the antibody to a specific site. Chen *et al.* (1994b) recently have described a single-chain antibody with specificity for the gp120 HIV protein that can be delivered by gene transfer. They have shown that human CD4+ T lymphocytes can be transduced to express this antibody intracellularly, and that cytopathic syncytium formation and HIV-1 production were inhibited, although not eliminated.

### PROSPECTUS

Human gene therapy, although still in the infant stages of development, offers the possibility for major advances in the prevention and treatment of myriad diseases. Gene therapy brings an entirely new paradigm for the treatment of disorders stemming from missing or defective genes, whether they are inherited or acquired. Furthermore, this technology likely also will evolve for the treatment of "nongenetic" illnesses, where the tissue-specific synthesis of a protein can be used for therapeutic benefit. The identification of new genes related to specific diseases will broaden the scope of applications. Currently, however, the clinical application of gene therapy is more limited by the availability of suitable gene transfer methodology than by the identification of suitable targets for genetic alteration. However, as increasing numbers of investigators address these issues, better reagents likely will emerge. Furthermore, a better understanding of the pathophysiological processes will permit the design of physiologically appropriate interventions. It is to be hoped that increased collaboration among physicians, molecular biologists, and cell biologists will result in the development of highly integrated approaches to this new form of therapy.

### BIBLIOGRAPHY

- Anderson, W.F., Blaese, R.M., and Culver, K. The ADA human gene therapy protocol. *Hum. Gene Ther.*, 1990, 1:331-341.
- Armentano, D., Sookdeo, C., White, G., Giuggio, V., Souza, D., Couture, L., Cardona, L., Vincent, K., Wadsworth, S., and Smith, A. Second generation adenovirus vectors for cystic fibrosis gene therapy. *J. Cell Biochem. Suppl.*, 1994, 18A:222.
- Barba, D., Hardin, J., Sadelain, M., and Gage, F.H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91:4348-4352.
- Batra, R.K., Wang-Johanning, F., Wagner, E., Garver, R.I., and Curiel, D.T. Receptor-mediated gene delivery employing lectin-binding specificity. *Gene Therapy*, 1994, 1:255-260.
- Bett, A.J., Haddara, W., Prevec, L., and Graham, F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91:8802-8806.
- Bodine, D.M., Moritz, T., Donahue, R.E., Luskey, B.D., Kessler, S.W., Martin, D.I.K., Orkin, S.H., Nienhuis, A.W., and Williams, D.A. Long-

## SECTION I GENERAL PRINCIPLES

- mune s'  
this h  
gro  
eo
- ...e adenosine deaminase gene in Rhee  
f multiple lineages after retroviral  
bone marrow cells. *Blood*, 1993,
- ...e, Warden, P., and Olsen, I. Correc  
tency by contact-mediated enzyme transfer af  
transplantation. *Transplantation*, 1993, 56:991-996.
- ...e, Chase, M., Wei, M.X., Tamiya, T., Hurford, R.K., Jr.,  
wall, N.W., Tepper, R.I., Breakefield, X.O., and Chiocca, E.A. Gene  
transfer into experimental brain tumors mediated by adenovirus, her  
pes simplex virus, and retrovirus vectors. *Hum. Gene Ther.*, 1994,  
5:183-191.
- Brigham, K., Meyrick, B., Christman, B., Magnuson, M., King, G., and  
Berry, L., *In vivo* transfection of murine lungs with a functioning  
prokaryotic gene using a liposome vehicle. *Am. J. Med. Sci.*, 1989,  
298:278-281.
- Canonico, A.E., Conary, J.T., Meyrick, B.O., and Brigham, K.L. Aerosol  
and intravenous transfection of human  $\alpha$  1-antitrypsin gene to lungs  
of rabbits. *Am. J. Resp. Cell. Mol. Biol.*, 1994, 10:24-29.
- Chen, S.-H., Shine, H.D., Goodman, J.C., Grossman, R.G., and Woo, S.L.  
Gene therapy for brain tumors: regression of experimental gliomas by  
adenovirus-mediated gene transfer *in vivo*. *Proc. Natl. Acad. Sci. U.S.A.*,  
1994a, 91:3054-3057.
- Chen, S.-Y., Bagley, J., and Marasco, W.A. Intracellular antibodies as a  
new class of therapeutic molecules for gene therapy. *Hum. Gene Ther.*,  
1994b, 5:595-601.
- Chowdhury, J.R., Grossman, M., Gupta, S., Chowdhury, N.R., Baker, J.R.,  
Jr., and Wilson, J.M. Long-term improvement of hypercholesterolemia  
after *ex vivo* gene therapy in LDLR-deficient rabbits. *Science*, 1991,  
254:1802-1805.
- Conary, J.T., Parker, R.E., Christman, B.W., Faulks, R.D., King, G.A.,  
Meyrick, B.O., and Brigham, K.L. Protection of rabbit lungs from endo  
toxin injury by *in vivo* hyperexpression of the prostaglandin G/H syn  
thase gene. *J. Clin. Invest.*, 1994, 93:1834-1840.
- Cristiano, R.J., Smith, L.C., Kay, M.A., Brinkley, B.R., and Woo, S.L.C.  
Hepatic gene therapy: efficient gene delivery and expression in pri  
mary hepatocytes utilizing a conjugated adenovirus-DNA complex.  
*Proc. Natl. Acad. Sci. USA*, 1993, 90:11548-11552.
- Culver, K.W., Anderson, W.F., and Blaese, R.M. Lymphocyte gene ther  
apy. *Hum. Gene Ther.*, 1991, 2:107-109.
- Davis, H.L., Demeneix, B.A., Quantin, B., Coulombe, J., and Whalen,  
R.G. Plasmid DNA is superior to viral vectors for direct gene transfer  
into adult mouse skeletal muscle. *Hum. Gene Ther.*, 1993, 4:733-740.
- Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose,  
K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R.C. Vac  
cination with irradiated tumor cells engineered to secrete murine  
granulocyte-macrophage colony-stimulating factor stimulates potent,  
specific, and long-lasting anti-tumor immunity. *Proc. Natl. Acad. Sci.  
U.S.A.*, 1993, 90:3539-3543.
- Engelhardt, J.F., Litzky, L., and Wilson, J.M. Prolonged transgene ex  
pression in cotton rat lung with recombinant adenovirus defective in  
E2a. *Human Gene Therapy*, 1994, 5:1217-1229.
- Felgner, P., Gadek, T., Holm, M., Roman, R., Chan, H.W., Wenz, M.,  
Northrop, J.P., Ringold, G.M., and Danielsen, M. Lipofection: a highly  
efficient, lipid-mediated DNA transfection procedure. *Proc. Natl. Acad.  
Sci. U.S.A.*, 1987, 84:7413-7417.
- Fisher, K.J., and Wilson, J.M. Biochemical and functional analysis of an  
adenovirus-based ligand complex for gene transfer. *Biochem. J.*, 1994,  
299:49-58.
- Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin,  
D.S., Moolten, F.L., and Abraham, G.N. The "bystander effect": tumor  
regression when a fraction of the tumor mass is genetically modified.  
*Cancer Res.*, 1993, 53:5274-5283.
- Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C., and  
Robinson, H.L. DNA vaccines: protective immunizations by parenteral,  
mucosal, and gene-gun inoculations. *Proc. Natl. Acad. Sci. U.S.A.*,  
1993, 90:11478-11482.
- Gottesman, M.M., Germann, U.A., Aksentijevich, I., Sugimoto, Y., Car  
darelli, C.O., and Pastan, I. Gene transfer of drug resistance genes: im  
plications for cancer therapy. *Ann. N.Y. Acad. Sci.*, 1994, 716:126-138.
- Graham, F.L., and Prevek, L. Manipulation of adenoviral vectors. In,  
*Methods in Molecular Biology: Gene Transfer and Expression Proto  
cols*. The Humana Press, Inc., Clifton, NJ, 1991, pp. 109-128.
- Greber, U.F., Willets, M., Webster, P., and Helenius, A. Stepwise dis  
mantling of adenovirus 2 during entry into cells. *Cell*, 1993, 75:477-486.
- Grossman, M., Raper, S.E., Kozarsky, K., Stein, E.A., Engelhardt, J.F.,  
Muller, D., Lupien, P.J., and Wilson, J.M. Successful *ex vivo* gene ther  
apy directed to liver in a patient with familial hypercholesterolemia.  
*Nat. Genet.*, 1994, 6:335-341.
- Horwitz, M.S. Adenoviruses. In *Virology*, 2nd ed. Raven Press, New York,  
1990, pp. 1723-1740.
- Hyde, S.C., Gill, D.R., Higgins, C.F., and Trezise, A.E.O. Correction of  
the ion transport defect in cystic fibrosis transgenic mice by gene ther  
apy. *Nature*, 1993, 362:250-255.
- Jolly, D. Viral vector systems for gene therapy. *Cancer Gene Therapy*,  
1994, 1:51-64.
- Kennedy, P.G.E., and Steiner, I. The use of herpes simplex virus vectors  
for gene therapy in neurological diseases. *Q. J. Med.*, 1993,  
86:697-702.
- Kotin, R.M. Prospects for the use of adeno-associated virus as a vector  
for human gene therapy. *Hum. Gene Ther.*, 1994, 5:793-801.
- Kozarsky, K.F., McKinley, D.R., Austin, L.L., Raper, S.E., Stratford  
-Perricaudet, L.D., and Wilson, J.M. *In vivo* correction of low density  
lipoprotein receptor deficiency in the Watanabe heritable hyperlipi  
demic rabbit with recombinant adenoviruses. *J. Biol. Chem.*, 1994,  
269:13695-13702.
- Krauss, J.C., Bond, L.M., Todd, R.F.I., and Wilson, J.M. Expression of  
retroviral transduced human CD18 in murine cells: an *in vitro* model  
of gene therapy for leukocyte adhesion deficiency. *Hum. Gene Ther.*,  
1991, 2:221-228.
- Ledley, T.S., and Ledley, F.D. Multicompartment, numerical model of  
cellular events in the pharmacokinetics of gene therapies. *Hum. Gene  
Ther.*, 1994, 5:679-691.
- Li, Y., McGowan, P., Hellstrom, I., Hellstrom, K.E., and Chen, L. Co  
-stimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7,  
a natural ligand for CD28, can be used to treat established mouse  
melanoma. *J. Immunol.*, 1994, 153:421-428.
- Lotze, M.T. Transplantation and adoptive cellular therapy of cancer: the  
role of T-cell growth-factors. *Cell Transplant.*, 1993, 2:33-47.
- Lotze, M.T., and Rubin, J.T. Gene therapy of cancer: a pilot study of IL  
-4 gene-modified fibroblasts admixed with autologous tumor to elicit  
an immune response. *Hum. Gene Ther.*, 1994, 5:41-55.
- Lotze, M.T., and Rubin, J.T. The treatment of patients with melanoma  
using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes.  
*Hum. Gene Ther.*, 1992, 3:167-177.
- Malim, M.H., Freimuth, W.W., Liu, J., Boyle, T.J., Lyerly, H.K., Cullen,  
B.R., and Nabel, G.J. Stable expression of transdominant Rev protein  
in human T cells inhibits human immunodeficiency virus replication.  
*J. Exp. Med.*, 1992, 176:1197-1201.
- Michael, S.I., and Curiel, D.T. Strategies to achieve targeted gene deliv  
ery via the receptor-mediated endocytosis pathway. *Gene Therapy*,  
1994, 1:223-232.

- ly modified.
- ro, J.C., and  
y parenteral,  
*Sci. U.S.A.*
- oto, Y., Car-  
e genes: im-  
'6:126-138.
- vectors. In,  
*ssion Proto-*  
-128.
- epwise dis-  
'5:477-486.
- lhardt, J.F.,  
o gene ther-  
sterolaemia.
- , New York,
- rection of  
/ gene ther-  
*ie Therapy,*
- rus vectors  
ed., 1993,
- as a vector  
01.
- Stratford-  
ow density  
hyperlipi-  
em., 1994,
- pression of  
/ vitro model  
*Gene Ther.*
- model of  
tum. *Gene*
- en, L. Co-  
tes by B7,  
ed mouse
- cancer: the  
47.
- udy of IL-  
or to elicit
- melanoma  
iphocytes.
- Cullen,  
ev protein  
application.
- ene deliv-  
*Therapy,*
- Miller, A.D., Miller, D.G., Garcia, J.V., and Lynch, C.M. Use of retroviral vectors for gene transfer and expression. *Methods Enzymol.*, 1993, 217:581-599.
- Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. *Cancer Res.*, 1986, 46:5276-5281.
- Moss, B. Poxviridae and their replication. In, *Virology*. Raven Press, New York, 1990, pp. 2079-2111.
- Moss, B., and Flexner, C. Vaccinia virus expression vectors. *Annu. Rev. Immunol.*, 1987, 5:305-324.
- Nabel, E.G., Plautz, G., Boyce, F.M., Stanley, J.C., and Nabel, G.J. Recombinant gene expression *in vivo* within endothelial cells of the arterial wall. *Science*, 1989, 244:1342-1344.
- Nabel, E.G., Plautz, G., and Nabel, G.J. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. *Proc. Natl. Acad. Sci. U.S.A.*, 1992, 89:5157-5161.
- Nabel, E.G., Plautz, G.E., and Nabel, G.J. Recombinant growth factor gene expression in vascular cells *in vivo*. *Ann. N.Y. Acad. Sci.*, 1994a, 714:247-252.
- Nabel, E.G., Shum, L., Pompili, V.J., Yang, Z.Y., San, H., Shu, H.B., Liptay, S., Gold, L., Gordon, D., Deryck, R., and Nabel, G.J. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. *Proc. Natl. Acad. Sci. U.S.A.*, 1993a, 90:107759-107763.
- Nabel, E.G., Yang, Z., Liptay, S., San, H., Gordon, D., Haudenschild, C.C., and Nabel, G.J. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia *in vivo*. *J. Clin. Invest.*, 1993b, 91:1822-1829.
- Nabel, E.G., Yang, Z.Y., Plautz, G., Forough, R., Zhan, X., Haudenschild, C.C., Maciag, T., and Nabel, G.J. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries *in vivo*. *Nature*, 1993c, 362:844-846.
- Nabel, G.J., Fox, B.A., Felgner, P., Shu, S., and Cho, K. Immunotherapy for cancer by direct gene transfer into tumors. *Hum. Gene Ther.*, 1994b, 5:57-77.
- Nabel, G.J., Fox, B.A., Post, L., Thompson, C.B., and Woffendin, C. A molecular genetic intervention for AIDS—effects of a transdominant negative form of Rev. *Hum. Gene Ther.*, 1994, 5:79-92.
- Neel, J.V. Germ-line gene therapy: another view. *Hum. Gene Ther.*, 1993, 4:127-128.
- Neufeld, E.F. Lysosomal storage diseases. *Annu. Rev. Biochem.*, 1991, 60:257-280.
- Nicolau, C., Le Pape, A., Soriano, P., Fargette, F., and Juhel, M-F. *In vivo* expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. *Proc. Natl. Acad. Sci. U.S.A.*, 1983, 80:1068-1072.
- Nienhuis, A.W., McDonagh, K.T., and Bodine, D.M. Gene transfer into hematopoietic stem cells. *Cancer*, 1991, 67:2700-2704.
- Ohno, T., Gordon, D., San, H., Pompili, V.J., Imperiale, M.J., Nabel, G.J., and Nabel, E.G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. *Science*, 1994, 265:781-784.
- Oldfield, E.H., Ram, Z., Culver, K.W., Blaese, R.M., DeVroom, H.L., and Anderson, W.F. Gene therapy for the treatment of brain tumors us-  
ing intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. *Hum. Gene Ther.*, 1993, 4:39-69.
- Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L., Merino, M.J., Culver, K., Miller, A.D., Blaese, R.M., and Anderson, W.F. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N. Engl. J. Med.*, 1990, 323:570-578.
- Rubin, B.A., and Rorke, L.B. Adenovirus vaccines. In, *Vaccines*, 2nd ed. W.B. Saunders, Philadelphia, 1994, pp. 474-502.
- Seth, P. Adenovirus-dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein. *J. Virol.*, 1994, 68:1204-1206.
- Tatum, E.L. Molecular biology, nucleic acids and the future of medicine. *Perspect. Biol. Med.*, 1966, 10:19-32.
- Tepper, R.I., and Mule, J.J. Experimental and clinical studies of cytokine gene-modified tumor cells. *Hum. Gene Ther.*, 1994, 5:153-164.
- Valyi-Nagy, T., Gesser, R.M., Raengsakulrach, B., Deshmone, S.L., Randazzo, B.P., Dillner, A.J., and Fraser, N.W. A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement. *Virology*, 1994, 199:484-490.
- Le van Beusechem, V.W., Kukler, A., Heidt, P.J., and Valerio, D. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. *Proc. Natl. Acad. Sci. U.S.A.*, 1992, 89:7640-7644.
- Walkley, S.U., Thrall, M.A., Dobrenis, K., Huang, M., March, P.A., Siegel, D.A., and Wurzelmann, S. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91:2970-2974.
- Wilson, J.M., Birinyi, L.K., Salomon, R.N., Libby, P., Callow, A.D., and Mulligan, R.C. Implantation of vascular grafts lined with genetically modified endothelial cells. *Science*, 1989, 244:1344-1346.
- Wolff, J.A., and Lederberg, J. An early history of gene transfer and therapy. *Hum. Gene Ther.*, 1994, 5:469-480.
- Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., and Felgner, P.L. Direct gene transfer into mouse muscle *in vivo*. *Science*, 1990, 247:1465-1468.
- Wu, G.Y., and Wu, C.H. Receptor-mediated *in vitro* gene transformation by a soluble DNA carrier system. *J. Biol. Chem.*, 1987, 262:4429-4432.
- Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gönczöl, E., and Wilson, J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91:4407-4411.
- Zabner, J., Couture, L.A., Gregory, R.J., Graham, S.M., Smith, A.E., and Welsh, M.J. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. *Cell*, 1993, 75:207-216.
- Zenke, M., Steinlein, P., Wagner, E., Cotten, M., Beug, H., and Birnstiel, M.L. Receptor-mediated endocytosis of transferrin-polycation conjugates: an effective way to introduce DNA into hematopoietic cells. *Proc. Natl. Acad. Sci. U.S.A.*, 1990, 87:3655-3659.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**